

Detection and localization of surgically resectable cancer test

Science

359, 926-930

DOI: [10.1126/science.aar3247](https://doi.org/10.1126/science.aar3247)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Developing DNA methylation-based diagnostic biomarkers. <i>Journal of Genetics and Genomics</i> , 2018, 45, 87-97.	1.7	41
2	Cancer detection: Seeking signals in blood. <i>Science</i> , 2018, 359, 866-867.	6.0	58
3	Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?. <i>Clinical Colorectal Cancer</i> , 2018, 17, e415-e433.	1.0	49
4	New Blood Test SEEKS To Detect and Localize Cancer before It's Too Late. <i>Biochemistry</i> , 2018, 57, 1561-1562.	1.2	1
5	The role of transvaginal ultrasound in screening for ovarian cancer. <i>Climacteric</i> , 2018, 21, 221-226.	1.1	16
6	IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?. <i>Endocrine Practice</i> , 2018, 24, 453-459.	1.1	22
7	A fluid solution. <i>Cancer</i> , 2018, 124, 1853-1854.	2.0	0
8	Smoking cessation drugs alone may not help people to quit. <i>Cancer</i> , 2018, 124, 1855-1855.	2.0	0
9	Liquid Biopsies. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 207-208.	0.3	1
10	Methylation in cell-free DNA for early cancer detection. <i>Annals of Oncology</i> , 2018, 29, 1351-1353.	0.6	22
11	Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management. <i>Gut</i> , 2018, 67, 1561-1563.	6.1	21
12	Circulating tumor DNA detection in hepatocellular carcinoma. <i>Annals of Oncology</i> , 2018, 29, 1094-1096.	0.6	4
13	Ovarian Cancer Prevention and Screening. <i>Obstetrics and Gynecology</i> , 2018, 131, 909-927.	1.2	176
14	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
15	Towards actionable health information: the expanding armory of laboratory cancer diagnostics. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 399-400.	0.4	0
16	Advances in the understanding of hereditary ataxia – implications for future patients. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 203-217.	0.5	0
17	Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges. <i>ACS Sensors</i> , 2018, 3, 540-560.	4.0	31
18	CancerSEEK and destroy – a blood test for early cancer detection. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 133-133.	12.5	22

#	ARTICLE	IF	CITATIONS
19	Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1871-1876.	3.3	48
20	Classification and interaction in random forests. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1690-1692.	3.3	150
21	The value of cell-free DNA for molecular pathology. Journal of Pathology, 2018, 244, 616-627.	2.1	91
22	Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Letters, 2018, 420, 228-235.	3.2	178
23	Advances in liquid biopsy approaches for early detection and monitoring of cancer. Genome Medicine, 2018, 10, 21.	3.6	85
24	Simultaneous Discovery of Cell-Free DNA and the Nucleosome Ladder. Genetics, 2018, 209, 27-29.	1.2	9
25	Focused Ultrasound-enabled Brain Tumor Liquid Biopsy. Scientific Reports, 2018, 8, 6553.	1.6	55
26	Auf dem Weg zu "actionable Health Information": Das wachsende Arsenal der Labordiagnostik bei Krebserkrankungen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 399-400.	0.4	0
27	Versatile graphene biosensors for enhancing human cell therapy. Biosensors and Bioelectronics, 2018, 117, 283-302.	5.3	23
28	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	5.8	178
29	There Will Be Blood Tests. Cell, 2018, 173, 1-3.	13.5	94
30	Debugging Nano-Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies. Trends in Biotechnology, 2018, 36, 755-769.	4.9	145
31	Role of circulating tumor DNA in the management of early-stage lung cancer. Thoracic Cancer, 2018, 9, 509-515.	0.8	25
32	Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 964-977.	1.8	19
33	Circulating Cell-free Tumor Nucleic Acids in Gastric Cancer. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018, 18, 168.	0.1	0
36	Multi-analyte assays and early detection of common cancers. Journal of Thoracic Disease, 2018, 10, S2165-S2167.	0.6	8
37	Liquid biopsy-based biomarkers for early detection of pancreatic cancer. Precision Cancer Medicine, 0, 1, 19-19.	1.8	0
38	A fluid future for liquid biopsies. Cancer Cytopathology, 2018, 126, 963-964.	1.4	1

#	ARTICLE	IF	CITATIONS
39	Application of Wild Macrofungi as Anticancer Therapeutics. <i>Fungal Biology</i> , 2018, , 243-274.	0.3	1
42	Deep Medical Image Computing in Preventive and Precision Medicine. <i>IEEE MultiMedia</i> , 2018, 25, 109-113.	1.5	6
43	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 103.	1.0	7
44	Precision in personalized prediction-based medicine. <i>Personalized Medicine</i> , 2018, 15, 467-470.	0.8	0
45	New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. <i>Npj Genomic Medicine</i> , 2018, 3, 31.	1.7	71
46	Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers. <i>Scientific Reports</i> , 2018, 8, 14321.	1.6	35
47	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , 2018, 563, 579-583.	13.7	624
48	Platelets in cancer development and diagnosis. <i>Biochemical Society Transactions</i> , 2018, 46, 1517-1527.	1.6	33
49	Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. <i>Gastroenterology</i> , 2018, 155, 2016-2018.e11.	0.6	29
50	Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1011-1019.	1.5	10
51	Universal cancer screening: revolutionary, rational, and realizable. <i>Npj Precision Oncology</i> , 2018, 2, 23.	2.3	77
52	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	670
53	One size does not fit all: Size-based plasma DNA diagnostics. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	27
54	Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. <i>Expert Reviews in Molecular Medicine</i> , 2018, 20, e6.	1.6	20
56	Advances in Next-Generation Sequencing Bioinformatics for Clinical Diagnostics. <i>Advances in Molecular Pathology</i> , 2018, 1, 149-166.	0.2	4
57	Stochastic Modeling of Steric Hindrance Effects in Biosensors. , 2018, , .		2
58	Noninvasive diagnostic imaging using machine-learning analysis of nanoresolution images of cell surfaces: Detection of bladder cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12920-12925.	3.3	76
59	Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8–9 February 2018. <i>Ecancelmedscience</i> , 2018, 12, 817.	0.6	3

#	ARTICLE	IF	CITATIONS
60	AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018, 11, 735-778.	0.7	36
61	Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 738-742.	1.2	24
62	Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2877.	1.8	275
63	The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 295.	1.0	30
64	Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation. <i>Journal of Immunological Methods</i> , 2018, 463, 27-38.	0.6	39
65	Early Detection of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 903-914.	0.9	102
66	Reply to the letter to the editor Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer™ by Yang et al.™ by V. Conteduca, U. De giorgi and G. Lauletta. <i>Annals of Oncology</i> , 2018, 29, 2021-2022.	0.6	0
67	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. <i>BMC Medicine</i> , 2018, 16, 166.	2.3	181
68	Potential of circulating biomarkers in liquid biopsy diagnostics. <i>BioTechniques</i> , 2018, 65, 187-189.	0.8	8
69	Small Molecule Nanodrug Assembled of Dual-Anticancer Drug Conjugate for Synergetic Cancer Metastasis Therapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 3495-3502.	1.8	27
70	Preamplification with dUTP and Cod UNG Enables Elimination of Contaminating Amplicons. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3185.	1.8	5
71	Liquid Biopsy in Gastrointestinal Cancers. <i>Diagnostics</i> , 2018, 8, 75.	1.3	11
72	Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review. <i>Indian Journal of Clinical Biochemistry</i> , 2018, 33, 382-386.	0.9	18
73	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10925-E10933.	3.3	140
74	Application of Cell-free DNA Analysis to Cancer Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 1754-1765.	13.9	634
75	Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. <i>Biomarkers in Medicine</i> , 2018, 12, 1197-1201.	0.6	3
76	The diagnostic work-up of cancer-associated myositis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 630-636.	2.0	37
77	Introduction to the Special Collection – Beating Cancer with Early Detection: A Seasoned Idea with New Insights. <i>Journal of Applied Laboratory Medicine</i> , The, 2018, 3, 155-158.	0.6	0

#	ARTICLE	IF	CITATIONS
78	Recent advances in colorectal cancer screening. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 139-147.	0.9	18
79	Tissue and plasma proteomics for early stage cancer detection. <i>Molecular Omics</i> , 2018, 14, 405-423.	1.4	28
80	Translational molecular imaging in exocrine pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2442-2455.	3.3	17
81	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 138-151.	1.0	0
82	Gold Nanoparticle Couples with Entropy-Driven Toehold-Mediated DNA Strand Displacement Reaction on Magnetic Beads: Toward Ultrasensitive Energy-Transfer-Based Photoelectrochemical Detection of miRNA-141 in Real Blood Sample. <i>Analytical Chemistry</i> , 2018, 90, 11892-11898.	3.2	102
83	Pre-diagnostic delays caused by gastrointestinal investigations do not affect outcomes in pancreatic cancer. <i>Annals of Medicine and Surgery</i> , 2018, 34, 66-70.	0.5	8
84	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. <i>Oncoscience</i> , 2018, 5, 209-211.	0.9	11
85	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	1.6	93
86	Circulating Tumor DNA for Early Cancer Detection. <i>journal of applied laboratory medicine, The</i> , 2018, 3, 300-313.	0.6	25
87	The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. <i>Yearbook of Medical Informatics</i> , 2018, 27, 211-222.	0.8	21
88	The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy. <i>Annals of Translational Medicine</i> , 2018, 6, 168-168.	0.7	1
89	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. <i>Cell Death and Disease</i> , 2018, 9, 894.	2.7	34
90	MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 274-282.	3.3	68
91	Simultaneous Quantification of Multiple Cancer Biomarkers in Blood Samples through DNA-Assisted Nanopore Sensing. <i>Angewandte Chemie</i> , 2018, 130, 12058-12063.	1.6	13
92	The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome. <i>Current Opinion in Pharmacology</i> , 2018, 41, 74-78.	1.7	14
93	Looking for trouble? Diagnostics expanding disease and producing patients. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 978-982.	0.9	16
94	Early detection: a long road ahead. <i>Nature Reviews Cancer</i> , 2018, 18, 401-401.	12.8	15
95	Automated 3D-Printed Microfluidic Array for Rapid Nanomaterial-Enhanced Detection of Multiple Proteins. <i>Analytical Chemistry</i> , 2018, 90, 7569-7577.	3.2	54

#	ARTICLE	IF	CITATIONS
96	Overcoming diagnostic issues in precision treatment of pancreatic cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 189-195.	0.4	1
97	Drug-Abuse Nanotechnology: Opportunities and Challenges. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2288-2298.	1.7	7
98	Organ-preserving approaches in oesophageal cancer. <i>Lancet Oncology</i> , The, 2018, 19, 858-859.	5.1	3
99	Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 455-467.	2.7	45
100	Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. <i>Cancer Letters</i> , 2018, 432, 84-92.	3.2	14
101	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5115-E5124.	3.3	114
102	Simultaneous Quantification of Multiple Cancer Biomarkers in Blood Samples through DNA-Assisted Nanopore Sensing. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 11882-11887.	7.2	77
103	Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5106-E5114.	3.3	107
104	Translational "omics: Future potential and current challenges in precision medicine. <i>Methods</i> , 2018, 151, 3-11.	1.9	22
105	Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2018, 1, 364-377.	2.6	21
106	Molecular mechanisms of the preventable causes of cancer in the United States. <i>Genes and Development</i> , 2018, 32, 868-902.	2.7	105
107	Early stage NSCLC " challenges to implementing ctDNA-based screening and MRD detection. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 577-586.	12.5	281
108	Circulating Tumor DNA Assays in Clinical Cancer Research. <i>Journal of the National Cancer Institute</i> , 2018, 110, 929-934.	3.0	60
109	Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. <i>Gastroenterology</i> , 2018, 155, 730-739.e3.	0.6	215
110	Latest development of liquid biopsy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1645-S1651.	0.6	62
111	Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA. <i>Advanced Science</i> , 2018, 5, 1800614.	5.6	52
112	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. <i>Drug Discovery Today</i> , 2018, 23, 1848-1872.	3.2	12
113	A novel method to detect the Mexican founder mutation BRCA1 ex9 ^{del} 12 associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan ² /2 probes. <i>Molecular Medicine Reports</i> , 2018, 18, 1531-1537.	1.1	4

#	ARTICLE	IF	CITATIONS
114	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5767-5771.	3.2	68
115	Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. <i>Scientific Reports</i> , 2018, 8, 11631.	1.6	41
116	Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. <i>Diagnostics</i> , 2018, 8, 31.	1.3	94
117	Liquid biopsies for hepatocellular carcinoma. <i>Translational Research</i> , 2018, 201, 84-97.	2.2	29
118	Sweet Predictions Speak Volumes for Early Detection of Pancreatic Cancer. <i>Gastroenterology</i> , 2018, 155, 265-268.	0.6	12
119	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018, 24, 4726-4733.	3.2	39
120	Compressive Force Spectroscopy: From Living Cells to Single Proteins. <i>International Journal of Molecular Sciences</i> , 2018, 19, 960.	1.8	5
121	The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1007.	1.8	50
122	Liquid Biopsy in Colorectal Cancer-Current Status and Potential Clinical Applications. <i>Micromachines</i> , 2018, 9, 300.	1.4	26
123	Combining plasma-based biosources to predict treatment response in NSCLC patients. <i>Annals of Oncology</i> , 2018, 29, 2018.	0.6	1
124	Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies. <i>Clinical Chemistry</i> , 2018, 64, 1522-1533.	1.5	42
125	Advanced antifouling zwitterionic layer based impedimetric HER2 biosensing in human serum: Glycoprofiling as a novel approach for breast cancer diagnostics. <i>Sensors and Actuators B: Chemical</i> , 2018, 272, 626-633.	4.0	28
126	Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2105-2114.	1.1	8
127	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
128	The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. <i>Current Oncology Reports</i> , 2018, 20, 70.	1.8	58
129	Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 575-581.	0.3	16
130	Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status. <i>Annals of Surgery</i> , 2018, 268, 408-420.	2.1	125
132	Circulating tumor DNA " Current state of play and future perspectives. <i>Pharmacological Research</i> , 2018, 136, 35-44.	3.1	31

#	ARTICLE	IF	CITATIONS
133	Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 395-403.	1.4	2
134	A star-shaped DNA probe based on strand displacement for universal and multiplexed fluorometric detection of genetic variations. <i>Mikrochimica Acta</i> , 2018, 185, 413.	2.5	10
136	Global Inequities in Precision Medicine and Molecular Cancer Research. <i>Frontiers in Oncology</i> , 2018, 8, 346.	1.3	44
137	Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1505403.	5.5	286
138	Lectin-based biosensors as analytical tools for clinical oncology. <i>Cancer Letters</i> , 2018, 436, 63-74.	3.2	20
139	Ultraspecific and Amplification-Free Quantification of Mutant DNA by Single-Molecule Kinetic Fingerprinting. <i>Journal of the American Chemical Society</i> , 2018, 140, 11755-11762.	6.6	43
140	Liquid biopsy for early stage lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S876-S881.	0.6	33
141	Molecular imaging and molecular diagnostics: two sides of the same coin?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1645-1648.	3.3	6
142	Precise predictive and therapeutic strategy for breast cancer. <i>Future Oncology</i> , 2018, 14, 1777-1780.	1.1	1
143	Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?. <i>Biomarkers in Cancer</i> , 2018, 10, 1179299X1877697.	3.6	4
145	A Step Closer to Cancer Screening by Blood Test. <i>Clinical Chemistry</i> , 2018, 64, 1420-1422.	1.5	4
146	Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection. <i>Trends in Cancer</i> , 2018, 4, 499-512.	3.8	89
147	A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. <i>PLoS ONE</i> , 2018, 13, e0196826.	1.1	22
148	Opportunities in biotechnology. <i>Journal of Biotechnology</i> , 2018, 282, 38-45.	1.9	14
149	Coupled Fluorometer-Potentiostat System and Metal-Free Monochromatic Luminophores for High-Resolution Wavelength-Resolved Electrochemiluminescent Multiplex Bioassay. <i>ACS Sensors</i> , 2018, 3, 1362-1367.	4.0	47
150	Plasma N-glycans in colorectal cancer risk. <i>Scientific Reports</i> , 2018, 8, 8655.	1.6	57
151	Advanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening. <i>Gynecologic Oncology Reports</i> , 2018, 24, 48-50.	0.3	3
152	Proteomics biomarkers for solid tumors: Current status and future prospects. <i>Mass Spectrometry Reviews</i> , 2019, 38, 49-78.	2.8	53

#	ARTICLE	IF	CITATIONS
153	Diabetes and Pancreatic Cancer: Both Cause and Effect. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1-2.	3.0	28
154	Expression profile of the amino acid transporters <sc>SLC</sc> 7A5, <sc>SLC</sc> 7A7, <sc>SLC</sc> 7A8 and the enzyme <sc>TDO</sc> 2 in basal cell carcinoma. <i>British Journal of Dermatology</i> , 2019, 180, 130-140.	1.4	26
155	Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030445.	2.9	33
156	Extraction of Cell-Free Whole Blood Plasma Using a Dielectrophoresis-Based Microfluidic Device. <i>Biotechnology Journal</i> , 2019, 14, 1800181.	1.8	23
157	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 372-379.	3.0	79
158	Circulating tumour DNA as a cancer biomarker. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 42-48.	0.8	13
159	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. <i>British Journal of Cancer</i> , 2019, 121, 483-489.	2.9	32
160	Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	197
161	A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. <i>Cancer Science</i> , 2019, 110, 2941-2959.	1.7	52
162	Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1183.	1.0	38
163	Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-10.	3.2	33
164	Cerumenogram: a new frontier in cancer diagnosis in humans. <i>Scientific Reports</i> , 2019, 9, 11722.	1.6	16
165	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , 2019, 11, 1152.	1.7	33
166	Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. <i>Cells</i> , 2019, 8, 863.	1.8	156
167	Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. <i>Cancers</i> , 2019, 11, 1164.	1.7	12
168	Circulating Hybrid Cells Join the Fray of Circulating Cellular Biomarkers. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 595-607.	2.3	24
169	Predictive biomarkers for drug response in bladder cancer. <i>International Journal of Urology</i> , 2019, 26, 1044-1053.	0.5	50
170	Next-generation sequencing in liquid biopsy: cancer screening and early detection. <i>Human Genomics</i> , 2019, 13, 34.	1.4	302

#	ARTICLE	IF	CITATIONS
171	An external quality assurance trial to assess mass spectrometry protein testing facilities for identifying multiple human peptides. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 6575-6581.	1.9	2
172	Screening for Pancreatic Cancer—Is There Hope?. <i>JAMA Internal Medicine</i> , 2019, 179, 1313.	2.6	6
173	Screening for Pancreatic Cancer Gets a D, but the Student Is Improving. <i>JAMA Surgery</i> , 2019, 154, 795.	2.2	8
174	Liquid biopsy for the detection and management of surgically resectable tumors. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 517-525.	0.8	6
175	New approaches for detecting cancer with circulating cell-free DNA. <i>BMC Medicine</i> , 2019, 17, 159.	2.3	21
176	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
177	Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAnceR Personalized Profiling by deep Sequencing. <i>Scientific Reports</i> , 2019, 9, 10426.	1.6	27
178	Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 31-41.	3.4	16
179	Use of Circulating Tumor DNA for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6909-6915.	3.2	34
180	Hepatobiliary cancers in South America: disparity strikes. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 581.	3.7	6
181	Analytical Platform with Selectable Assay Parameters Based on Three Functions of Magnetic Nanoparticles: Demonstration of Highly Sensitive Rapid Quantitation of Staphylococcal Enterotoxin B in Food. <i>Analytical Chemistry</i> , 2019, 91, 9852-9857.	3.2	45
182	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. <i>Cell Death and Disease</i> , 2019, 10, 534.	2.7	78
183	Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges. <i>Cancers</i> , 2019, 11, 950.	1.7	73
184	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	3.2	21
185	“Hey Ciri, What’s My Prognosis?” <i>Cell</i> , 2019, 178, 518-520.	13.5	6
186	Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 151-160.	0.9	36
187	Novel Approaches to Ovarian Cancer Screening. <i>Current Oncology Reports</i> , 2019, 21, 75.	1.8	56
188	The biological functions and clinical applications of exosomes in lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4613-4633.	2.4	90

#	ARTICLE	IF	CITATIONS
189	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 358-367.	1.2	13
190	Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6546-6553.	3.2	45
191	Omics Approaches in Pancreatic Adenocarcinoma. <i>Cancers</i> , 2019, 11, 1052.	1.7	8
192	Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung. <i>BMC Cancer</i> , 2019, 19, 741.	1.1	10
193	Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor <scp>DNA</scp>. <i>Molecular Oncology</i> , 2019, 13, 1623-1650.	2.1	64
194	Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, S1252-S1256.	0.6	7
195	Primary and Secondary Prevention of Pancreatic Cancer. <i>Current Epidemiology Reports</i> , 2019, 6, 119-137.	1.1	0
196	<p>Update on liquid biopsy in clinical management of non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5097-5109.	1.0	51
197	Circulating Tumor DNA and Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2019, 39, 452-462.	1.8	27
198	Bioinformatics Tools and Workflow to Select Blood Biomarkers for Early Cancer Diagnosis: An Application to Pancreatic Cancer. <i>Proteomics</i> , 2019, 19, e1800489.	1.3	22
199	Progress in quantitative technique of circulating cell free DNA and its role in cancer diagnosis and prognosis. <i>Cancer Genetics</i> , 2019, 239, 75-84.	0.2	5
200	Clinical Use of Cell-Free DNA in Tumor Diagnostics. <i>Advances in Molecular Pathology</i> , 2019, 2, 153-162.	0.2	0
201	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. <i>Cells</i> , 2019, 8, 1251.	1.8	53
202	Identification of a haptoglobin-hemoglobin complex in human blood plasma. <i>Journal of Inorganic Biochemistry</i> , 2019, 201, 110802.	1.5	15
203	Thermodynamics and kinetics guided probe design for uniformly sensitive and specific DNA hybridization without optimization. <i>Nature Communications</i> , 2019, 10, 4675.	5.8	28
204	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. <i>Cancer Cell</i> , 2019, 36, 350-368.	7.7	204
205	A Multifunctional Platinum Nanoreactor for Point-of-Care Metabolic Analysis. <i>Matter</i> , 2019, 1, 1669-1680.	5.0	88
206	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019, 10, 4666.	5.8	146

#	ARTICLE	IF	CITATIONS
207	Liquid biopsy tracking of lung tumor evolutions over time. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1099-1108.	1.5	50
208	Study on evaluation of emergency plan for production accident. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 304, 042074.	0.2	0
209	Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers. <i>Nature Biomedical Engineering</i> , 2019, 3, 183-193.	11.6	324
210	BBcancer: an expression atlas of blood-based biomarkers in the early diagnosis of cancers. <i>Nucleic Acids Research</i> , 2020, 48, D789-D796.	6.5	29
211	Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1222.	1.3	14
212	Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5498.	1.8	23
213	Antibodies against aberrant glycans as cancer biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1057-1068.	1.5	10
214	An integrated and automated electronic system for point-of-care protein testing. , 2019, 2019, 1571-1574.		4
215	Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2019, 39, 75.	3.7	27
216	Conversion Surgery for Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1945.	1.0	20
217	Mutations found in cell-free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. <i>Cancer Science</i> , 2019, 110, 3375-3381.	1.7	16
218	DNA Methylation Cancer Biomarkers: Translation to the Clinic. <i>Frontiers in Genetics</i> , 2019, 10, 1150.	1.1	301
219	Glycan Analysis as Biomarkers for Testicular Cancer. <i>Diagnostics</i> , 2019, 9, 156.	1.3	2
220	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , 2019, 11, 1181.	1.7	16
221	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2019, 19, 553-567.	12.8	393
222	Applications of liquid biopsies for cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	151
223	Multimodality Approaches to Screening for Lung Cancer. <i>Clinical Oncology</i> , 2019, 31, 702-705.	0.6	2
225	A New Robust Deep Canonical Correlation Analysis Algorithm for Small Sample Problems. <i>IEEE Access</i> , 2019, 7, 33631-33639.	2.6	3

#	ARTICLE	IF	CITATIONS
226	Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. <i>BMC Cancer</i> , 2019, 19, 832.	1.1	110
227	Fragmentation patterns of circulating cell-free DNA demonstrate biomarker potential for human cancers. <i>Biotarget</i> , 2019, 3, 16-16.	0.5	6
228	The current status of the clinical utility of liquid biopsies in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1031-1041.	1.5	27
229	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. <i>Cancer Treatment Reviews</i> , 2019, 80, 101894.	3.4	37
230	Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping. <i>Communications Biology</i> , 2019, 2, 325.	2.0	138
231	Novel breast cancer screening: combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis. <i>Scientific Reports</i> , 2019, 9, 13595.	1.6	51
233	Liquid biopsy: Where did it come from, what is it, and where is it going?. <i>Investigative and Clinical Urology</i> , 2019, 60, 139.	1.0	9
234	Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1426.	1.7	27
235	The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors. <i>Neuro-Oncology</i> , 2019, 21, 1509-1518.	0.6	46
236	Liquid biopsy: one cell at a time. <i>Npj Precision Oncology</i> , 2019, 3, 23.	2.3	72
237	Liquid biopsy: a holy grail for cancer detection. <i>Biomarkers in Medicine</i> , 2019, 13, 991-994.	0.6	4
238	Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance. <i>Radiotherapy and Oncology</i> , 2019, 131, 52-59.	0.3	23
239	Unravelling the lipocalin 2 interaction with aptamers: May rolling circle amplification improve their functional affinity?. <i>Talanta</i> , 2019, 197, 406-412.	2.9	12
240	Pushing the limits of electrochemistry toward challenging applications in clinical diagnosis, prognosis, and therapeutic action. <i>Chemical Communications</i> , 2019, 55, 2563-2592.	2.2	48
241	Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual. <i>Advances in Clinical Chemistry</i> , 2019, 89, 131-188.	1.8	9
242	Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. <i>Annals of Oncology</i> , 2019, 30, 358-359.	0.6	57
243	Cell-free DNA Analysis in Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 501-502.	13.9	12
244	Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 617-628.	1.7	61

#	ARTICLE	IF	CITATIONS
245	Clinical factors associated with circulating tumor <sc>DNA</sc> (ct<sc>DNA</sc>) in primary breast cancer. <i>Molecular Oncology</i> , 2019, 13, 1033-1046.	2.1	30
246	Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. <i>Human Genetics</i> , 2019, 138, 109-124.	1.8	146
247	Liquid biopsy in breast cancer: A comprehensive review. <i>Clinical Genetics</i> , 2019, 95, 643-660.	1.0	210
248	Early detection and therapeutics. <i>Molecular Oncology</i> , 2019, 13, 599-613.	2.1	17
249	Hollow Core Inhibited Coupling Fibers for Biological Optical Sensing. <i>Journal of Lightwave Technology</i> , 2019, 37, 2598-2604.	2.7	12
250	Optimization of Dose Schedules for Chemotherapy of Early Colon Cancer Determined by High-Performance Computer Simulations. <i>Cancer Informatics</i> , 2019, 18, 117693511882280.	0.9	9
251	Epigenomics of Pancreatic Cancer: A Critical Role for Epigenome-Wide Studies. <i>Epigenomes</i> , 2019, 3, 5.	0.8	3
252	Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core. <i>Biosensors and Bioelectronics</i> , 2019, 131, 24-29.	5.3	29
253	Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. <i>Journal of Pathology</i> , 2019, 247, 641-649.	2.1	53
254	Precision Medicine: Disruptive Technology in the Modern Hospital. , 2019, , 121-131.		0
255	Barcoded point-of-care bioassays. <i>Chemical Society Reviews</i> , 2019, 48, 850-884.	18.7	120
256	Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips. <i>RSC Advances</i> , 2019, 9, 1859-1868.	1.7	56
257	<p>Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3207-3221.	1.0	68
258	Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response. <i>Cancers</i> , 2019, 11, 825.	1.7	7
259	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
260	CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. <i>Cell Systems</i> , 2019, 9, 9-23.e8.	2.9	83
261	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	9.4	315
262	Evaluating diagnostic strategies for early detection of cancer: the CanTest framework. <i>BMC Cancer</i> , 2019, 19, 586.	1.1	34

#	ARTICLE	IF	CITATIONS
263	Artificial Intelligence and Personalized Medicine. <i>Cancer Treatment and Research</i> , 2019, 178, 265-283.	0.2	150
264	A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals. <i>Molecular and Cellular Oncology</i> , 2019, 6, e1614419.	0.3	2
265	Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. <i>Theranostics</i> , 2019, 9, 4130-4140.	4.6	59
266	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz042.	1.4	22
267	Mutated clones are the new normal. <i>Science</i> , 2019, 364, 938-939.	6.0	28
268	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. <i>Drug Discovery Today</i> , 2019, 24, 1715-1719.	3.2	10
269	Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. <i>Future Oncology</i> , 2019, 15, 1805-1810.	1.1	0
270	Helical-Like 3D Ultrathin Piezoelectric Element for Complicated Ultrasonic Field. <i>Advanced Functional Materials</i> , 2019, 29, 1902912.	7.8	15
271	Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 3761-3769.	1.3	35
272	The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 596-603.	0.6	10
273	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	13.7	764
275	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.	3.2	118
276	Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age. , 2019, , 105-113.		0
277	Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients. <i>BMC Medical Genomics</i> , 2019, 12, 78.	0.7	11
278	Improving early detection of cancers by profiling extracellular vesicles. <i>Expert Review of Proteomics</i> , 2019, 16, 545-547.	1.3	3
279	Primary Bone Tumor of the Spine—An Evolving Field: What a General Spine Surgeon Should Know. <i>Global Spine Journal</i> , 2019, 9, 108S-116S.	1.2	22
280	Liquid Biopsy in Hepatocellular Carcinoma. , 2019, , 87-95.		0
281	A Novel Blood-Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein. <i>Advanced Science</i> , 2019, 6, 1802115.	5.6	24

#	ARTICLE	IF	CITATIONS
283	Circulating biomarkers for early detection and clinical management of colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019, 69, 107-122.	2.7	214
284	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	3.4	152
285	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1124.	3.4	538
286	Early Cancer Detection from Multianalyte Blood Test Results. <i>IScience</i> , 2019, 15, 332-341.	1.9	20
287	Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. <i>Cancer Research</i> , 2019, 79, 2798-2804.	0.4	111
288	Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	20
289	Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 52-66.	0.5	1
290	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6026-6034.	3.2	50
291	Serum Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 107-117.	0.0	0
292	Early-Stage NSCLC: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 968-978.	0.5	35
293	Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. <i>International Journal of Medical Informatics</i> , 2019, 128, 79-86.	1.6	81
294	Liquid Biopsy: General Concepts. <i>Acta Cytologica</i> , 2019, 63, 449-455.	0.7	186
295	Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing. <i>Clinical Chemistry</i> , 2019, 65, 916-926.	1.5	25
296	Urine-Based Liquid Biopsy for Nonurological Cancers. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 277-283.	0.3	38
297	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
298	An Old Concept with a New Twist. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 230-232.	0.3	1
299	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
300	A roadmap for the clinical implementation of optical-imaging biomarkers. <i>Nature Biomedical Engineering</i> , 2019, 3, 339-353.	11.6	52

#	ARTICLE	IF	CITATIONS
301	Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?. <i>Cancer Research</i> , 2019, 79, 2462-2465.	0.4	45
302	Passenger mutations accurately classify human tumors. <i>PLoS Computational Biology</i> , 2019, 15, e1006953.	1.5	39
303	Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e672.	0.6	9
304	Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. <i>Journal of Hepatology</i> , 2019, 71, 409-421.	1.8	31
305	Life and death of circulating cell-free DNA. <i>Cancer Biology and Therapy</i> , 2019, 20, 1057-1067.	1.5	327
306	A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1813.	1.8	96
307	RNA sequencing and swarm intelligence-enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA. <i>Nature Protocols</i> , 2019, 14, 1206-1234.	5.5	84
308	Polyethylene glycol improves current methods for circulating extracellular vesicle-derived DNA isolation. <i>Journal of Translational Medicine</i> , 2019, 17, 75.	1.8	55
309	Current Status and Future Prospects of Clinically Exploiting Cancer-specific Metabolism-Why Is Tumor Metabolism Not More Extensively Translated into Clinical Targets and Biomarkers?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1385.	1.8	12
310	Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2019, 51, 126-134.	0.3	16
311	Cancer Treatment in the Genomic Era. <i>Annual Review of Biochemistry</i> , 2019, 88, 247-280.	5.0	24
313	The emerging role of cell-free DNA as a molecular marker for cancer management. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100087.	7.0	375
314	Time-Gated Luminescence Acquisition for Biochemical Sensing: miRNA Detection. <i>Springer Series on Fluorescence</i> , 2019, , 213-267.	0.8	5
315	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 918-927.	1.1	26
316	Thermophoretically enriched detection. <i>Nature Biomedical Engineering</i> , 2019, 3, 163-164.	11.6	7
317	COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5223-5232.	3.3	34
318	Tumor-educated platelets. <i>Blood</i> , 2019, 133, 2359-2364.	0.6	120
319	Optimizing Precision Medicine for Public Health. <i>Frontiers in Public Health</i> , 2019, 7, 42.	1.3	58

#	ARTICLE	IF	CITATIONS
320	Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. <i>Cancers</i> , 2019, 11, 396.	1.7	20
321	Genomic Medicine—Progress, Pitfalls, and Promise. <i>Cell</i> , 2019, 177, 45-57.	13.5	143
322	Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. <i>Seminars in Liver Disease</i> , 2019, 39, 153-162.	1.8	5
323	Liquid biopsy in newly diagnosed patients with locoregional (I-IIIa) non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 419-427.	1.5	16
324	Liquid Biopsy in Solid Malignancy. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 284-296.	0.3	13
325	Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. <i>Interface Focus</i> , 2019, 9, 20180077.	1.5	53
326	The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. <i>Molecular Cancer</i> , 2019, 18, 36.	7.9	48
327	Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6308-6312.	3.3	127
328	Circulating Tumor DNA: A Step into the Future of Cancer Management. <i>Acta Cytologica</i> , 2019, 63, 456-465.	0.7	13
329	Integrated microfluidic pneumatic circuit for point-of-care molecular diagnostics. <i>Biosensors and Bioelectronics</i> , 2019, 133, 169-176.	5.3	28
330	Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 903-909.	1.1	20
331	The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 129.	1.3	61
332	Cell-free tumour <i>scp>DNA</scp></i> testing for early detection of cancer — a potential future tool. <i>Journal of Internal Medicine</i> , 2019, 286, 118-136.	2.7	50
333	Thermopneumatic suction integrated microfluidic blood analysis system. <i>PLoS ONE</i> , 2019, 14, e0208676.	1.1	15
334	A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. <i>Theranostics</i> , 2019, 9, 1280-1287.	4.6	45
335	Novel Graphene Biosensor Based on the Functionalization of Multifunctional Nano-bovine Serum Albumin for the Highly Sensitive Detection of Cancer Biomarkers. <i>Nano-Micro Letters</i> , 2019, 11, 20.	14.4	49
336	Diagnostic potential of <i>scp>TERT</scp></i> promoter and <i>scp>FGFR</scp>3</i> mutations in urinary cell-free <i>scp>DNA</scp></i> in upper tract urothelial carcinoma. <i>Cancer Science</i>, 2019, 110, 1771-1779.</i>	1.7	63
337	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2019, 37, 153-164.	0.8	135

#	ARTICLE	IF	CITATIONS
338	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	0.8	66
339	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	23
340	Liquid biopsy for cancer diagnosis and screening – The promise and challenges. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 420-423.	0.8	1
341	Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 5168.	1.6	15
342	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
343	Genetics of Familial and Sporadic Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 2041-2055.	0.6	52
344	Early Detection of Pancreatic Cancer: Opportunities and Challenges. <i>Gastroenterology</i> , 2019, 156, 2024-2040.	0.6	476
345	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. <i>Clinical Epigenetics</i> , 2019, 11, 59.	1.8	106
346	Liquid biopsy and minimal residual disease – latest advances and implications for cure. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 409-424.	12.5	671
347	Oncosuppressor-Mutated Cells as a Liquid Biopsy Test for Cancer-Screening. <i>Scientific Reports</i> , 2019, 9, 2384.	1.6	9
348	Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 172-186.	4.0	393
349	Coimmunocapture and Electrochemical Quantitation of Total and Phosphorylated Amyloid- β Monomers. <i>Analytical Chemistry</i> , 2019, 91, 3539-3545.	3.2	23
350	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	157.7	965
351	Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 704.	1.8	44
352	Cancer epigenetics in solid organ tumours: A primer for surgical oncologists. <i>European Journal of Surgical Oncology</i> , 2019, 45, 736-746.	0.5	16
353	Lung Cancer Screening, towards a Multidimensional Approach: Why and How?. <i>Cancers</i> , 2019, 11, 212.	1.7	31
354	Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 521-529.	1.5	20
355	Recent advances in circulating nucleic acids in oncology. <i>Annals of Oncology</i> , 2019, 30, 374-384.	0.6	69

#	ARTICLE	IF	CITATIONS
356	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	3.6	66
357	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Research, 2019, 29, 418-427.	2.4	159
358	Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Medicine, 2019, 11, 11.	3.6	127
359	Biomarkers of Exposure and Responses to Ionizing Radiation. , 2019, , 757-786.		3
360	Barcode-free next-generation sequencing error validation for ultra-rare variant detection. Nature Communications, 2019, 10, 977.	5.8	13
361	Considerations and quality controls when analyzing cell-free tumor DNA. Biomolecular Detection and Quantification, 2019, 17, 100078.	7.0	66
362	Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow-up. International Journal of Cancer, 2019, 145, 1090-1098.	2.3	12
363	Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cellular and Molecular Life Sciences, 2019, 76, 2477-2486.	2.4	59
364	Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. Apmis, 2019, 127, 329-336.	0.9	16
365	Early detection and monitoring of cancer in liquid biopsy: advances and challenges. Expert Review of Molecular Diagnostics, 2019, 19, 273-276.	1.5	16
366	Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection. Molecular and Cellular Proteomics, 2019, 18, 865a-875.	2.5	41
367	Clonal hematopoiesis: background player in plasma cell-free DNA variants. Annals of Translational Medicine, 2019, 7, S384-S384.	0.7	4
368	Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan. Annals of Gastroenterological Surgery, 2019, 3, 581-591.	1.2	34
369	Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Scientific Reports, 2019, 9, 16971.	1.6	39
370	Lectin biosensors in cancer glycan biomarker detection. Advances in Clinical Chemistry, 2019, 93, 1-61.	1.8	27
371	Validation and evaluation of a common biomarker in human cancers sera protein detected by a monoclonal antibody UNIVmAb. BMC Research Notes, 2019, 12, 744.	0.6	2
372	Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer—a clinical biomarker discovery and validation study. Clinical Epigenetics, 2019, 11, 158.	1.8	83
373	CPEM: Accurate cancer type classification based on somatic alterations using an ensemble of a Random forest and a deep neural network. Scientific Reports, 2019, 9, 16927.	1.6	21

#	ARTICLE	IF	CITATIONS
374	The importance of circulating and disseminated tumor cells in pancreatic cancer. <i>Surgery Open Science</i> , 2019, 1, 49-55.	0.5	2
375	External validation of a panel of plasma microRNA biomarkers for lung cancer. <i>Biomarkers in Medicine</i> , 2019, 13, 1557-1564.	0.6	8
376	Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019. <i>BioMed Research International</i> , 2019, 2019, 1-11.	0.9	12
377	Combined use of salivary biomarkers and carcinoembryonic antigen for lung cancer detection in a Chinese population. <i>Medicine (United States)</i> , 2019, 98, e16511.	0.4	6
378	A fluorescent probe for simultaneously sensing NTR and hNQO1 and distinguishing cancer cells. <i>Journal of Materials Chemistry B</i> , 2019, 7, 6822-6827.	2.9	23
379	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1</i> -rearranged lung cancer. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004630.	0.5	13
380	Technological Challenges and Future Issues for the Detection of Circulating MicroRNAs in Patients With Cancer. <i>Frontiers in Chemistry</i> , 2019, 7, 815.	1.8	24
381	A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms. <i>Cancers</i> , 2019, 11, 1872.	1.7	15
382	Triggers of Autoimmunity: The Role of Bacterial Infections in the Extracellular Exposure of Lupus Nuclear Autoantigens. <i>Frontiers in Immunology</i> , 2019, 10, 2608.	2.2	70
383	Ovarian cancer detection by DNA methylation in cervical scrapings. <i>Clinical Epigenetics</i> , 2019, 11, 166.	1.8	22
385	A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 2029.	1.0	49
386	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1809.	1.7	17
387	The Gasdermin E gene Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types. <i>Cancers</i> , 2019, 11, 1810.	1.7	24
388	Personalized precision medicine. <i>Bio-Algorithms and Med-Systems</i> , 2019, 15, .	1.0	4
389	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
390	Predicting health and life span with the deep plasma proteome. <i>Nature Medicine</i> , 2019, 25, 1815-1816.	15.2	12
391	Common and rare sequence variants influencing tumor biomarkers in blood. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 29, cebp.1060.2018.	1.1	9
392	Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer. , 2019, , 325-367.		2

#	ARTICLE	IF	CITATIONS
393	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S265-S279.	1.3	17
395	The Translational Status of Cancer Liquid Biopsies. <i>Regenerative Engineering and Translational Medicine</i> , 2021, 7, 312-352.	1.6	39
396	Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans. <i>Nature Communications</i> , 2019, 10, 5735.	5.8	22
397	Circulating DNA, a Potentially Sensitive and Specific Diagnostic Tool for Future Medicine. <i>Dose-Response</i> , 2019, 17, 155932581989101.	0.7	1
398	Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1266.	1.3	39
399	Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. <i>Clinical Cancer Research</i> , 2019, 25, 7396-7404.	3.2	33
400	Straight-to-test for the two-week-wait colorectal cancer pathway under the updated NICE guidelines reduces time to cancer diagnosis and treatment. <i>Annals of the Royal College of Surgeons of England</i> , 2019, 101, 333-339.	0.3	14
401	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
402	Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis. <i>Oncologist</i> , 2019, 24, e603-e606.	1.9	16
403	Circulating tumor DNA (ctDNA) in precision oncology of ovarian cancer. <i>Pharmacogenomics</i> , 2019, 20, 1251-1253.	0.6	2
404	Electrochemical Impedance Spectroscopy Based Biosensors: Mechanistic Principles, Analytical Examples and Challenges towards Commercialization for Assays of Protein Cancer Biomarkers. <i>ChemElectroChem</i> , 2019, 6, 989-1003.	1.7	114
405	Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. <i>Hepatology</i> , 2019, 69, 1180-1192.	3.6	138
406	Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. <i>Digestive Surgery</i> , 2019, 36, 462-469.	0.6	23
407	Are liquid biopsies ready for primetime?. <i>Cancer</i> , 2019, 125, 834-837.	2.0	2
408	Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential. <i>Methods in Molecular Biology</i> , 2019, 1909, 31-46.	0.4	0
409	Current Approaches to Pancreatic Cancer Screening. <i>American Journal of Pathology</i> , 2019, 189, 22-35.	1.9	43
410	Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?. <i>Acta Oncologica</i> , 2019, 58, S42-S48.	0.8	1
411	Cancer biomarker discovery and translation: proteomics and beyond. <i>Expert Review of Proteomics</i> , 2019, 16, 93-103.	1.3	107

#	ARTICLE	IF	CITATIONS
412	A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 330-345.	1.4	16
413	Liquid Biopsy for the Management of Patients with Colorectal Cancer. <i>Digestion</i> , 2019, 99, 39-45.	1.2	54
414	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the "U" out of "CUP". <i>British Journal of Cancer</i> , 2019, 120, 141-153.	2.9	71
415	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320.	1.9	15
416	Time to abandon early detection cancer screening. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13062.	1.7	22
417	Current and future perspectives of liquid biopsies in genomics-driven oncology. <i>Nature Reviews Genetics</i> , 2019, 20, 71-88.	7.7	912
418	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. <i>Journal of Thoracic Oncology</i> , 2019, 14, 16-24.	0.5	100
419	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 1205-1227.	5.0	21
420	Liquid Biopsy and Genomic Assessment for Lung Cancer. , 2019, , 165-180.		0
421	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019, 72, 135-139.	1.0	28
422	Liquid biopsy: novel technologies and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 312-316.	1.4	35
423	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 19-28.	1.1	20
424	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 171-182.	2.0	93
425	Glycomics of prostate cancer: updates. <i>Expert Review of Proteomics</i> , 2019, 16, 65-76.	1.3	25
426	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 108-118.e4.	0.6	270
427	Biophysicochemical Motifs in T-cell Receptor Sequences Distinguish Repertoires from Tumor-Infiltrating Lymphocyte and Adjacent Healthy Tissue. <i>Cancer Research</i> , 2019, 79, 1671-1680.	0.4	79
428	The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. <i>Clinical Cancer Research</i> , 2019, 25, 2745-2754.	3.2	32
429	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. <i>Journal of Thoracic Oncology</i> , 2019, 14, 343-357.	0.5	306

#	ARTICLE	IF	CITATIONS
430	<i>Dnase13</i> deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 641-649.	3.3	134
431	Can Grail find the trail to early cancer detection?. Clinical Chemistry and Laboratory Medicine, 2019, 57, 403-406.	1.4	9
432	Poly(noradrenalin) based bi-enzyme biosensor for ultrasensitive multi-analyte determination. Talanta, 2019, 194, 343-349.	2.9	17
433	Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. Translational Research, 2019, 205, 77-91.	2.2	98
434	Using a Modified Lymphocyte Genome Sensitivity (LGS) test or TumorScan test to detect cancer at an early stage in each individual. FASEB BioAdvances, 2019, 1, 32-39.	1.3	4
435	Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics. Proteomics, 2019, 19, e1700448.	1.3	73
436	Cell-free DNA in cancer: current insights. Cellular Oncology (Dordrecht), 2019, 42, 13-28.	2.1	34
437	Liquid biopsies. Genes Chromosomes and Cancer, 2019, 58, 219-232.	1.5	117
438	Screening and Diagnosis. , 2019, , 41-47.		0
439	Circulating Tumor DNA: Clinical Monitoring and Early Detection. Annual Review of Cancer Biology, 2019, 3, 187-201.	2.3	6
440	The search for a new test of early cancer detection. Clinical Chemistry and Laboratory Medicine, 2019, 57, e139-e140.	1.4	0
441	Machine Learning and Imaging Informatics in Oncology. Oncology, 2020, 98, 344-362.	0.9	40
442	Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1101-1110.	0.9	55
443	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. Molecular Imaging and Biology, 2020, 22, 47-65.	1.3	4
444	Demonstrating the feasibility of collecting secondary, deidentified data on Australian patients receiving treatment as part of a Medicine Access Programme. Internal Medicine Journal, 2020, 50, 99-104.	0.5	2
445	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. Acta Clinica Belgica, 2020, 75, 9-18.	0.5	9
446	The Different Facets of Liquid Biopsy: A Kaleidoscopic View. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037333.	2.9	24
447	Circulating cell-free tumor DNA analysis in pediatric cancers. Molecular Aspects of Medicine, 2020, 72, 100819.	2.7	24

#	ARTICLE	IF	CITATIONS
448	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 823-834.	1.2	29
449	When Results From Multitarget DNA Tests Are Positive and Colonoscopy Is Negative, Should We Be Concerned About Cancer Outside the Colon?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 783-786.	2.4	2
450	Strategies for Colorectal Cancer Screening. <i>Gastroenterology</i> , 2020, 158, 418-432.	0.6	343
451	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
452	Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. <i>Cancer Letters</i> , 2020, 468, 59-71.	3.2	113
453	Integrating Artificial and Human Intelligence: A Partnership for Responsible Innovation in Biomedical Engineering and Medicine. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 247-263.	1.0	57
454	Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 146, 1445-1456.	2.3	67
455	The potential of ctDNA analysis in breast cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 54-72.	2.7	22
456	Point: Circulating Tumor DNA for Modern Cancer Management. <i>Clinical Chemistry</i> , 2020, 66, 143-145.	1.5	6
457	Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100828.	2.7	104
458	Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. <i>Molecular Oncology</i> , 2020, 14, 8-21.	2.1	23
459	Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 527-532.	1.4	33
460	Current and future approaches to screening for endometrial cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 79-97.	1.4	35
462	Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 10.	1.8	41
463	An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. <i>Oncologist</i> , 2020, 25, e60-e67.	1.9	9
464	Liquid Biopsy Applications in the Clinic. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 125-132.	1.6	33
465	A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification. <i>Hormones and Cancer</i> , 2020, 11, 17-33.	4.9	19
466	Microfluidic systems for cancer diagnostics. <i>Current Opinion in Biotechnology</i> , 2020, 65, 37-44.	3.3	71

#	ARTICLE	IF	CITATIONS
467	Liquid biopsy analysis in cancer diagnostics. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100839.	2.7	11
468	Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 253-269.	2.7	28
469	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020, 69, 7-17.	6.1	357
470	Liquid Biopsy for Cancer: Review and Implications for the Radiologist. <i>Radiology</i> , 2020, 294, 5-17.	3.6	52
471	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 183-192.	3.2	79
472	PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2289-2314.	2.4	10
473	Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100831.	2.7	9
474	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. <i>Clinical Chemistry</i> , 2020, 66, 105-116.	1.5	26
475	Liquid biopsies and molecular imaging: friends or foes?. <i>Clinical and Translational Imaging</i> , 2020, 8, 47-50.	1.1	3
476	WDR74 induces nuclear β -catenin accumulation and activates Wnt-responsive genes to promote lung cancer growth and metastasis. <i>Cancer Letters</i> , 2020, 471, 103-115.	3.2	24
477	Circulating tumor DNA as an early cancer detection tool. , 2020, 207, 107458.		123
479	Deep learning of pharmacogenomics resources: moving towards precision oncology. <i>Briefings in Bioinformatics</i> , 2020, 21, 2066-2083.	3.2	43
480	The future of precision medicine. , 2020, , 561-569.		0
481	The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination. <i>Bioinformatics</i> , 2020, 36, 2217-2223.	1.8	29
482	In Pursuit of Zero 2.0: Recent Developments in Nonfouling Polymer Brushes for Immunoassays. <i>Advanced Materials</i> , 2020, 32, e1903285.	11.1	45
483	Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. <i>Annals of Surgery</i> , 2020, 271, 245-256.	2.1	54
484	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	260
485	Biomarkers in Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 115-127.	0.8	46

#	ARTICLE	IF	CITATIONS
486	Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers. <i>Pancreas</i> , 2020, 49, 1141-1152.	0.5	8
487	Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies. <i>Cancers</i> , 2020, 12, 2610.	1.7	8
488	Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2020, 159, 811-819.	0.6	8
489	MEMS Biosensors and COVID-19: Missed Opportunity. <i>ACS Sensors</i> , 2020, 5, 3297-3305.	4.0	28
490	Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer. <i>Molecular Biology Reports</i> , 2020, 47, 8159-8168.	1.0	12
491	The Potential of Circular RNAs as Cancer Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2541-2555.	1.1	19
492	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers</i> , 2020, 12, 2914.	1.7	26
493	Recent developments and ongoing trials in transplant oncology. <i>Liver International</i> , 2020, 40, 2326-2344.	1.9	6
494	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	7.7	52
495	Liquid biopsy approaches for pleural effusion in lung cancer patients. <i>Molecular Biology Reports</i> , 2020, 47, 8179-8187.	1.0	20
496	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 134.	6.9	36
497	Non-Invasive Early Molecular Detection of Gastric Cancers. <i>Cancers</i> , 2020, 12, 2880.	1.7	23
498	Plasmonic assay for amplification-free cancer biomarkers detection in clinical tissue samples. <i>Analytica Chimica Acta</i> , 2020, 1139, 111-118.	2.6	10
499	UegWeek 2020 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2020, 8, 144-887.	1.6	7
500	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction. <i>American Journal of Human Genetics</i> , 2020, 107, 882-894.	2.6	37
501	Biomarkers and Strategies for Early Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2504-2512.	1.1	53
502	Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers. <i>Cells</i> , 2020, 9, 2017.	1.8	30
504	The Metastatic Cascade as the Basis for Liquid Biopsy Development. <i>Frontiers in Oncology</i> , 2020, 10, 1055.	1.3	27

#	ARTICLE	IF	CITATIONS
505	Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature Communications, 2020, 11, 3475.	5.8	341
506	Potential of Using Cell-Free DNA and miRNA in Breast Milk to Screen Early Breast Cancer. BioMed Research International, 2020, 2020, 1-11.	0.9	5
507	Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses. Briefings in Bioinformatics, 2020, 21, 1182-1195.	3.2	29
508	A Cancer Diagnosis Method Combining miRNA-lncRNA Interaction Pairs and Class Weight Competition. IEEE Access, 2020, 8, 67059-67074.	2.6	4
509	Advances in the early diagnosis of hepatocellular carcinoma. Genes and Diseases, 2020, 7, 308-319.	1.5	189
510	Machine learning of serum metabolic patterns encodes early-stage lung adenocarcinoma. Nature Communications, 2020, 11, 3556.	5.8	151
511	Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 722-730.	1.3	7
513	The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers. Cancers, 2020, 12, 3343.	1.7	11
514	Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact. Cancers, 2020, 12, 3382.	1.7	16
515	Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform. Frontiers in Bioengineering and Biotechnology, 2020, 8, 581157.	2.0	11
516	Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2416-2422.	1.1	17
517	The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2396-2400.	1.1	4
518	Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine, 2020, 62, 103100.	2.7	44
519	Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response. Chinese Medical Journal, 2020, 133, 2476-2485.	0.9	17
520	Precision Detection Technology: Equipping Precision Oncology with Wings. Journal of Oncology, 2020, 2020, 1-8.	0.6	5
521	Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Annals of Gastroenterological Surgery, 2020, 4, 352-359.	1.2	4
522	Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future. Hamostaseologie, 2020, 40, 270-279.	0.9	12
523	Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1973-1982.	1.1	6

#	ARTICLE	IF	CITATIONS
525	Selenium-Containing Nanomaterials for Cancer Treatment. <i>Cell Reports Physical Science</i> , 2020, 1, 100111.	2.8	46
526	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	1.7	49
527	Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 1965.	1.7	31
528	Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening. <i>Advanced Science</i> , 2020, 7, 2000486.	5.6	19
529	Facile fluorescent aptasensor using aggregation-induced emission luminogens for exosomal proteins profiling towards liquid biopsy. <i>Biosensors and Bioelectronics</i> , 2020, 168, 112520.	5.3	55
530	Recent technologies enhancing the clinical utility of circulating tumor DNA. <i>Clinica Chimica Acta</i> , 2020, 510, 498-506.	0.5	3
531	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	7.7	179
534	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3112.	1.7	23
535	Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. <i>Cancers</i> , 2020, 12, 2988.	1.7	16
536	Core-Shell Multifunctional Nanomaterial-Based All-in-One Nanoplatfom for Simultaneous Multilayer Imaging of Dual Types of Tumor Biomarkers and Photothermal Therapy. <i>Analytical Chemistry</i> , 2020, 92, 15169-15178.	3.2	31
537	The Outcomes of Scientific Debates Should Be Published: The Arivale Story. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1070-1075.	0.6	5
538	Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in Early Cancer Detection?. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1372-1377.	0.6	18
539	Development of circulating tumour DNA analysis for gastrointestinal cancers. <i>ESMO Open</i> , 2020, 5, e000600.	2.0	20
540	The Liquid Biopsy in the Management of Colorectal Cancer: An Overview. <i>Biomedicines</i> , 2020, 8, 308.	1.4	44
541	Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood. <i>Current Treatment Options in Oncology</i> , 2020, 21, 89.	1.3	2
542	Direct kinetic fingerprinting and digital counting of single protein molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22815-22822.	3.3	35
543	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2025-2034.	6.1	77
544	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2597-2605.e4.	2.4	73

#	ARTICLE	IF	CITATIONS
546	Genetic Colorectal Cancer and Adenoma Risk Variants Are Associated with Increasing Cumulative Adenoma Counts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2269-2276.	1.1	7
547	Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance. <i>Journal of Gastroenterology</i> , 2020, 55, 1183-1193.	2.3	24
548	Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options. <i>Molecular Medicine</i> , 2020, 26, 88.	1.9	11
549	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. <i>Journal of Personalized Medicine</i> , 2020, 10, 94.	1.1	12
550	A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. <i>Cancers</i> , 2020, 12, 2410.	1.7	27
552	Metasurface-Enhanced Lab-on-a-Fiber Biosensors. <i>Laser and Photonics Reviews</i> , 2020, 14, 2000180.	4.4	58
553	Novel Approaches to Screening for Breast Cancer. <i>Radiology</i> , 2020, 297, 266-285.	3.6	77
554	World Lung Day: what, why, and where to?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L527-L533.	1.3	6
555	Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIREST) Regime. <i>Frontiers in Immunology</i> , 2020, 11, 1996.	2.2	5
556	Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy. <i>Case Reports in Oncology</i> , 2020, 13, 896-903.	0.3	2
557	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. <i>Clinical Cancer Research</i> , 2020, 26, 6310-6320.	3.2	15
558	Chasing ctDNA in Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e351-e360.	1.8	8
559	Landscape of circulating diagnostic biomarkers in pancreatic malignancies. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 5-5.	1.2	1
560	Early detection of pancreatic cancer. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 456-461.	1.0	19
561	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	59
562	Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology. <i>Frontiers in Pharmacology</i> , 2020, 11, 1177.	1.6	34
563	A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. <i>Cancers</i> , 2020, 12, 2247.	1.7	18
564	Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 709-716.	5.2	83

#	ARTICLE	IF	CITATIONS
565	Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9457.	1.8	56
566	Sequence-Specific Detection of DNA Strands Using a Solid-State Nanopore Assisted by Microbeads. <i>Micromachines</i> , 2020, 11, 1097.	1.4	1
567	Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098010.	0.8	3
568	Utility of Circulating Tumor DNA in Different Clinical Scenarios of Breast Cancer. <i>Cancers</i> , 2020, 12, 3797.	1.7	4
569	Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers. <i>Frontiers in Digital Health</i> , 2020, 2, 573010.	1.5	3
570	Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3704.	1.7	18
571	Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. <i>Journal of Hematology and Oncology</i> , 2020, 13, 170.	6.9	25
572	A mathematical model of ctDNA shedding predicts tumor detection size. <i>Science Advances</i> , 2020, 6, .	4.7	105
573	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2441-2453.	1.1	5
574	Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. <i>Visceral Medicine</i> , 2020, 36, 388-396.	0.5	4
575	Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. <i>Journal of Translational Medicine</i> , 2020, 18, 413.	1.8	24
576	Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms. <i>Glycoconjugate Journal</i> , 2020, 37, 703-711.	1.4	9
577	Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3234.	1.7	39
578	Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 943-956.	1.2	17
579	The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2401-2410.	1.1	13
580	Electrochemical aptasensors for cancer diagnosis in biological fluids – A review. <i>Analytica Chimica Acta</i> , 2020, 1124, 1-19.	2.6	62
581	Microbial Diagnostics for Cancer: A Step Forward but Not Prime Time Yet. <i>Cancer Cell</i> , 2020, 37, 625-627.	7.7	1
582	SinoDuplex: An Improved Duplex Sequencing Approach to Detect Low-frequency Variants in Plasma cfDNA Samples. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 81-90.	3.0	8

#	ARTICLE	IF	CITATIONS
583	The Utility of Liquid Biopsies in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 873-886.	0.4	14
584	Microbial DNA signature in plasma enables cancer diagnosis. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 453-454.	12.5	5
585	Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study. <i>Cancers</i> , 2020, 12, 1256.	1.7	32
586	Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression. <i>Cancers</i> , 2020, 12, 1268.	1.7	8
587	Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1541.	1.0	38
588	Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification. <i>Journal of Proteome Research</i> , 2020, 19, 2563-2574.	1.8	51
589	Functional Landscape of Dysregulated MicroRNAs in Oral Squamous Cell Carcinoma: Clinical Implications. <i>Frontiers in Oncology</i> , 2020, 10, 619.	1.3	27
590	Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. <i>Cancers</i> , 2020, 12, 1147.	1.7	20
591	Modeling EV Kinetics for Use in Early Cancer Detection. <i>Advanced Biology</i> , 2020, 4, e1900305.	3.0	33
592	Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study. <i>Radiation Oncology</i> , 2020, 15, 132.	1.2	13
593	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	15.2	216
594	UltraPrep is a scalable, cost-effective, bead-based method for purifying cell-free DNA. <i>PLoS ONE</i> , 2020, 15, e0231854.	1.1	5
595	Circulating microRNAs: Next-generation Cancer Detection. <i>Keio Journal of Medicine</i> , 2020, 69, 88-96.	0.5	10
596	Cell free DNA biology and its involvement in breast carcinogenesis. <i>Advances in Clinical Chemistry</i> , 2020, 97, 171-223.	1.8	6
597	Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 895-902.	1.1	36
598	Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. <i>Cancers</i> , 2020, 12, 1376.	1.7	23
599	The changing landscape of cancer in the USA - opportunities for advancing prevention and treatment. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 631-649.	12.5	32
600	Translational new frontiers in lung cancer research. <i>Shanghai Chest</i> , 2020, 4, 16-16.	0.3	0

#	ARTICLE	IF	CITATIONS
601	Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 95.	7.1	3
602	Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician's Point of View. <i>Journal of Clinical Medicine</i> , 2020, 9, 1790.	1.0	2
603	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1041-1043.	15.2	161
604	Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1070-1086.	1.2	48
605	Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy. <i>Current Gastroenterology Reports</i> , 2020, 22, 32.	1.1	14
606	Applying Serum Proteins and MicroRNA as Novel Biomarkers for Early-Stage Cervical Cancer Detection. <i>Scientific Reports</i> , 2020, 10, 9033.	1.6	14
607	Simultaneous Sensing of Multiple Cancer Biomarkers by a Single DNA Nanoprobe in a Nanopore. <i>Analytical Chemistry</i> , 2020, 92, 9405-9411.	3.2	24
608	Towards multi-cancer screening using liquid biopsies. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 525-526.	12.5	11
609	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	116
610	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705.	12.5	178
611	Assessment of Clinician Decision-making on Cancer Screening Cessation in Older Adults With Limited Life Expectancy. <i>JAMA Network Open</i> , 2020, 3, e206772.	2.8	16
612	Oncology Scan: Radiation Biology and Genomic Predictors of Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 393-397.	0.4	0
613	Detection of bladder cancer using urinary cell-free DNA and cellular DNA. <i>Clinical and Translational Medicine</i> , 2020, 9, 4.	1.7	43
614	A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma. <i>Cell</i> , 2020, 182, 317-328.e10.	13.5	53
615	Pan-Cancer Early Detection: Hype or Hope?. <i>Cancer Cell</i> , 2020, 38, 23-24.	7.7	20
616	Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection. <i>Cancers</i> , 2020, 12, 1629.	1.7	20
617	New Tests and Devices for Early Cancer Detection. <i>IEEE Pulse</i> , 2020, 11, 2-6.	0.1	0
618	Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance. <i>Clinical Cancer Research</i> , 2020, 26, 3104-3109.	3.2	66

#	ARTICLE	IF	CITATIONS
619	The fragmentation patterns of maternal plasma cell-free DNA and its applications in non-invasive prenatal testing. <i>Prenatal Diagnosis</i> , 2020, 40, 911-917.	1.1	11
620	Liquid biopsies for early cancer detection. , 2020, , 233-259.		5
621	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	3.3	50
622	Ovarian cancer screening: Current status and future directions. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 32-45.	1.4	68
623	Polyacrylamide/Phytic Acid/Polydopamine Hydrogel as an Efficient Substrate for Electrochemical Enrichment of Circulating Cell-Free DNA from Blood Plasma. <i>ACS Omega</i> , 2020, 5, 5365-5371.	1.6	6
624	A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. <i>Communications Biology</i> , 2020, 3, 134.	2.0	72
625	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	5.7	309
626	Tracking cancer progression: from circulating tumor cells to metastasis. <i>Genome Medicine</i> , 2020, 12, 31.	3.6	201
627	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. <i>European Radiology</i> , 2020, 30, 4496-4503.	2.3	7
628	Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	40
629	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
630	FeOOH@Metal-Organic Framework Core-Satellite Nanocomposites for the Serum Metabolic Fingerprinting of Gynecological Cancers. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 10831-10835.	7.2	113
631	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	58
632	Diagnosis and prognosis of myocardial infarction on a plasmonic chip. <i>Nature Communications</i> , 2020, 11, 1654.	5.8	83
633	Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform. <i>Biomedical Microdevices</i> , 2020, 22, 23.	1.4	28
634	State of the art and trends of circulating cancer biomarkers. <i>International Journal of Biological Markers</i> , 2020, 35, 12-15.	0.7	9
635	Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics. <i>BioEssays</i> , 2020, 42, e1900122.	1.2	9
636	Early detection of pancreatic cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 698-710.	3.7	258

#	ARTICLE	IF	CITATIONS
637	Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection. <i>Scientific Reports</i> , 2020, 10, 4124.	1.6	23
638	Combining liquid biopsies and PET-CT for early cancer detection. <i>Nature Medicine</i> , 2020, 26, 1010-1011.	15.2	7
639	Evaluation of predictive role of carcinoembryonic antigen and salivary mRNA biomarkers in gastric cancer detection. <i>Medicine (United States)</i> , 2020, 99, e20419.	0.4	7
640	Criteria for evaluating risk prediction of multiple outcomes. <i>Statistical Methods in Medical Research</i> , 2020, 29, 3492-3510.	0.7	8
641	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. <i>Cancers</i> , 2020, 12, 1672.	1.7	50
642	Improving Multi-Tumor Biomarker Health Check-Up Tests with Machine Learning Algorithms. <i>Cancers</i> , 2020, 12, 1442.	1.7	16
643	Fast and precise quantification of serum biomarkers and simultaneous recognition of multiple diseases enabled by a stable isotope-labelled peptides assisted high-throughput MRM strategy. <i>Analyst</i> , 2020, 145, 5299-5306.	1.7	0
644	Clinical Perspective and Translational Oncology of Liquid Biopsy. <i>Diagnostics</i> , 2020, 10, 443.	1.3	28
645	Noninvasive biomarkers for lung cancer diagnosis, where do we stand?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3317-3330.	0.6	21
646	Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease. <i>Journal of Proteome Research</i> , 2020, 19, 4219-4232.	1.8	63
647	Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas. <i>Trends in Cancer</i> , 2020, 6, 910-923.	3.8	17
648	Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. <i>Lung Cancer</i> , 2020, 146, 327-334.	0.9	14
649	Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma. <i>EBioMedicine</i> , 2020, 56, 102811.	2.7	40
651	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	4
652	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. <i>Genome Medicine</i> , 2020, 12, 20.	3.6	25
653	Refining Cancer Management Using Integrated Liquid Biopsy. <i>Theranostics</i> , 2020, 10, 2374-2384.	4.6	39
654	Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis of Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding. <i>Diagnostics</i> , 2020, 10, 120.	1.3	7
655	Combined use of circulating tumor cells and salivary mRNA to detect non-small-cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e19097.	0.4	8

#	ARTICLE	IF	CITATIONS
656	Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer. <i>Trends in Cancer</i> , 2020, 6, 78-81.	3.8	58
657	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020, 12, 23.	3.6	66
658	Leukobiopsy – A Possible New Liquid Biopsy Platform for Detecting Oncogenic Mutations. <i>Frontiers in Pharmacology</i> , 2019, 10, 1608.	1.6	6
659	Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer. <i>Annals of Oncology</i> , 2020, 31, 395-403.	0.6	75
661	Tracking myeloma tumor DNA in peripheral blood. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101146.	0.7	7
662	Techniques of endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 807-812.	0.9	8
663	MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020, 11, 762-768.	0.8	30
664	Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer. <i>European Journal of Cancer</i> , 2020, 127, 30-40.	1.3	19
665	Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. <i>Hepatology Communications</i> , 2020, 4, 284-297.	2.0	53
666	An integrated model for bead-based immunoassays. <i>Biosensors and Bioelectronics</i> , 2020, 154, 112070.	5.3	6
667	Liquid Biopsies for Hepatocellular Cancer and Their Potential in Clinical Practice. <i>Hepatology</i> , 2020, 71, 2160-2162.	3.6	5
668	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	6.0	351
669	Applications of probability and statistics in cancer genomics. <i>Quantitative Biology</i> , 2020, 8, 95-108.	0.3	1
670	Tumor-educated platelets for the earlier detection of hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 794-795.	0.7	4
671	Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 517-528.	1.5	60
672	Protein-protein correlations based variable dimension expansion algorithm for high efficient serum biomarker discovery. <i>Analytica Chimica Acta</i> , 2020, 1119, 25-34.	2.6	8
673	Methylation-mediated silencing of the LIM homeobox 6 (LHX6) gene promotes cell proliferation in human pancreatic cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 626-632.	1.0	6
674	Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures. <i>Clinica Chimica Acta</i> , 2020, 507, 39-53.	0.5	14

#	ARTICLE	IF	CITATIONS
675	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 748-756.	1.2	11
676	Activity-Based Diagnostics: An Emerging Paradigm for Disease Detection and Monitoring. <i>Trends in Molecular Medicine</i> , 2020, 26, 450-468.	3.5	51
677	Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas. <i>Diagnostics</i> , 2020, 10, 192.	1.3	9
678	Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. <i>Theranostics</i> , 2020, 10, 4544-4556.	4.6	85
679	Omicron-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. <i>Hepatology Research</i> , 2020, 50, 817-830.	1.8	13
680	Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3671-3690.	2.4	20
681	Structure Engineering of a Lanthanide-Based Metal-Organic Framework for the Regulation of Dynamic Ranges and Sensitivities for Pheochromocytoma Diagnosis. <i>Advanced Materials</i> , 2020, 32, e2000791.	11.1	33
682	Metabolic Fingerprinting on Synthetic Alloys for Medulloblastoma Diagnosis and Radiotherapy Evaluation. <i>Advanced Materials</i> , 2020, 32, e2000906.	11.1	93
683	Early-Stage Lung Cancer Diagnosis by Deep Learning-Based Spectroscopic Analysis of Circulating Exosomes. <i>ACS Nano</i> , 2020, 14, 5435-5444.	7.3	248
684	FeOOH@Metal-Organic Framework Core-Satellite Nanocomposites for the Serum Metabolic Fingerprinting of Gynecological Cancers. <i>Angewandte Chemie</i> , 2020, 132, 10923-10927.	1.6	14
685	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020, 31, 745-759.	0.6	770
686	Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4931-4943.	1.6	4
687	The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time. <i>Breast Cancer Management</i> , 2020, 9, .	0.2	12
688	Using methylation signatures on cell-free DNA for early cancer detection: a new era in liquid biopsy?. <i>Annals of Oncology</i> , 2020, 31, 665-667.	0.6	8
689	Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6551.	1.6	34
690	Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2431-2440.	1.1	23
691	A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3248-3258.	3.2	64
692	CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 1624-1627.	2.5	7

#	ARTICLE	IF	CITATIONS
693	Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. <i>European Respiratory Review</i> , 2020, 29, 190052.	3.0	87
694	Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 69.	3.5	18
695	Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2568-2574.	1.1	26
696	Convolutional neural network models for cancer type prediction based on gene expression. <i>BMC Medical Genomics</i> , 2020, 13, 44.	0.7	103
697	Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. <i>International Journal of Biological Sciences</i> , 2020, 16, 1551-1562.	2.6	99
698	Identifying the tissues-of-origin of circulating cell-free DNAs is a promising way in noninvasive diagnostics. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	15
699	The predictive and prognostic significance of cell-free DNA concentration in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 387-395.	1.3	17
700	Liver regeneration and liver metastasis. <i>Seminars in Cancer Biology</i> , 2021, 71, 86-97.	4.3	17
701	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	3.6	104
702	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. <i>Nature Reviews Nephrology</i> , 2021, 17, 245-261.	4.1	278
703	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1845-1858.	0.7	5
704	Liquid biopsies: Potential and challenges. <i>International Journal of Cancer</i> , 2021, 148, 528-545.	2.3	146
705	Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic <i>KLF4</i> mutations predominantly in low-grade regions. <i>Gut</i> , 2021, 70, 928-939.	6.1	48
706	It's in Our Blood: A Glimpse of Personalized Medicine. <i>Trends in Molecular Medicine</i> , 2021, 27, 20-30.	3.5	26
707	Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. <i>Cancer Science</i> , 2021, 112, 454-464.	1.7	15
708	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 199-222.	9.6	16
709	Photonic Technologies for Liquid Biopsies: Recent Advances and Open Research Challenges. <i>Laser and Photonics Reviews</i> , 2021, 15, .	4.4	10
710	Progress in Screening for Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 43-58.	0.6	7

#	ARTICLE	IF	CITATIONS
711	Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN. <i>Gastroenterology</i> , 2021, 160, 1345-1358.e11.	0.6	60
712	The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103166.	2.0	49
713	Adverse outcome pathways, key events, and radiation risk assessment. <i>International Journal of Radiation Biology</i> , 2021, 97, 804-814.	1.0	17
714	Next-Generation Liquid Biopsies: Embracing Data Science in Oncology. <i>Trends in Cancer</i> , 2021, 7, 283-292.	3.8	42
715	Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel. <i>Analytical Chemistry</i> , 2021, 93, 1059-1067.	3.2	22
716	Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection Test. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 460-468.	1.1	68
717	Blueprint for cancer research: Critical gaps and opportunities. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 107-139.	157.7	47
718	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , 2021, 160, 1373-1383.e6.	0.6	77
719	Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 793-834.	1.3	10
720	Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2021, 81, 39-45.	0.6	9
721	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. <i>Clinical Cancer Research</i> , 2021, 27, 226-236.	3.2	15
722	5m-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma. <i>Molecular Oncology</i> , 2021, 15, 138-150.	2.1	12
723	Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals. <i>European Respiratory Journal</i> , 2021, 57, 2002682.	3.1	21
724	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. <i>British Journal of Cancer</i> , 2021, 124, 345-358.	2.9	238
725	Quantitative STAU2 measurement in lymphocytes for breast cancer risk assessment. <i>Scientific Reports</i> , 2021, 11, 915.	1.6	4
726	Artificial intelligence in pancreaticobiliary endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 25-30.	1.4	6
727	The prospect of using liquid biopsy in diagnosis and treatment strategy in patients with carcinomas of unknown primary. <i>Uspehi Molekularnoj Onkologii</i> , 2021, 7, 10-19.	0.1	0
728	Biochemical Indicators of Cholangiocarcinoma. , 2021, , 163-178.		0

#	ARTICLE	IF	CITATIONS
729	LDH-doped electrospun short fibers enable dual drug loading and multistage release for chemotherapy of drug-resistant cancer cells. <i>New Journal of Chemistry</i> , 2021, 45, 13421-13428.	1.4	15
730	Decoding the Tissue of Origin of Cellular Damage from Cell-Free DNA in Liquid Biopsies. , 2021, , 365-378.		2
732	SequencErr: measuring and suppressing sequencer errors in next-generation sequencing data. <i>Genome Biology</i> , 2021, 22, 37.	3.8	15
733	IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread. <i>Clinical and Translational Immunology</i> , 2021, 10, e1330.	1.7	13
734	Liquid biopsy enters the clinic – implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	12.5	609
735	Circulating DNA Quantification. , 2021, , 413-426.		0
736	The Present and Future of Screening in Breast Cancer Prevention. , 2021, , 163-173.		0
737	Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer. <i>Biomedicines</i> , 2021, 9, 48.	1.4	14
738	Liq_ccRCC: Identification of Clear Cell Renal Cell Carcinoma Based on the Integration of Clinical Liquid Indices. <i>Frontiers in Oncology</i> , 2020, 10, 605769.	1.3	0
739	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. <i>Advances in Cancer Research</i> , 2021, 151, 231-304.	1.9	8
740	Application of Next Generation Sequencing in Laboratory Medicine. <i>Annals of Laboratory Medicine</i> , 2021, 41, 25-43.	1.2	99
741	A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. <i>Theranostics</i> , 2021, 11, 6214-6224.	4.6	13
742	Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma. <i>Methods in Molecular Biology</i> , 2021, 2261, 151-191.	0.4	8
743	Extracellular Vesicles in Chemoresistance. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 211-245.	1.0	3
744	Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2021, 12, 1258-1269.	1.2	11
745	Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 215-244.	0.8	0
746	Biomarkers in lung cancer screening: a narrative review. <i>Current Challenges in Thoracic Surgery</i> , 0, .	0.2	1
747	A Vision of the Future. , 2021, , 175-185.		0

#	ARTICLE	IF	CITATIONS
748	Application of a Novel Metallomics Tool to Probe the Fate of Metal-Based Anticancer Drugs in Blood Plasma: Potential, Challenges and Prospects. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 48-58.	1.0	7
749	The role of liquid biopsies in prostate cancer management. <i>Lab on A Chip</i> , 2021, 21, 3263-3288.	3.1	9
750	Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 1576-1589.	2.0	27
751	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. <i>Diagnostics</i> , 2021, 11, 103.	1.3	33
752	Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1514-1520.	0.7	11
753	Circulating tumor DNA detection and its application status in gastric cancer: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 529-536.	0.4	5
754	Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy. <i>Molecular Cancer</i> , 2021, 20, 23.	7.9	23
755	Criteria for Evaluating Multi-cancer Early Detection Tests. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 3.	0.1	9
756	Changing Etiology and Epidemiology of Human Liver Cancer. , 2021, , 13-29.		0
757	Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. <i>Nature Communications</i> , 2021, 12, 11.	5.8	121
758	Detection of Uveal Melanoma by Multiplex Immunoassays of Serum Biomarkers. <i>Methods in Molecular Biology</i> , 2021, 2265, 447-459.	0.4	3
759	Application of Single Cell Technology in Colorectal Cancer. , 2021, , 1-13.		0
760	Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 949-960.	1.9	111
761	Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study. <i>Thrombosis Update</i> , 2021, 2, 100030.	0.4	3
762	Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients. <i>Scientific Reports</i> , 2021, 11, 221.	1.6	21
763	Multi-Omic Biomarkers as Potential Tools for the Characterisation of Pancreatic Cystic Lesions and Cancer: Innovative Patient Data Integration. <i>Cancers</i> , 2021, 13, 769.	1.7	13
764	Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients. <i>PLoS ONE</i> , 2021, 16, e0245488.	1.1	13
765	Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring. <i>Genes</i> , 2021, 12, 349.	1.0	93

#	ARTICLE	IF	CITATIONS
766	Molecular biomarkers in early stage lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1165-1185.	1.3	23
767	Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study. <i>Clinical Epigenetics</i> , 2021, 13, 26.	1.8	19
768	Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 51.	1.8	13
769	Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer. <i>Diagnostics</i> , 2021, 11, 375.	1.3	7
770	Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. <i>ESMO Open</i> , 2021, 6, 100021.	2.0	13
771	PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23720.	0.9	4
772	Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. <i>Molecular Cancer</i> , 2021, 20, 34.	7.9	42
773	Circulating Cancer Biomarkers. <i>Cancers</i> , 2021, 13, 802.	1.7	20
774	Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 806.	1.7	67
775	2D graphene oxide-aptamer conjugate materials for cancer diagnosis. <i>Npj 2D Materials and Applications</i> , 2021, 5, .	3.9	53
776	Clinical management and biology of tumor dormancy in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 78, 49-62.	4.3	24
777	High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. <i>Clinical Cancer Research</i> , 2021, 27, 2523-2532.	3.2	17
778	Targeted proteomics-derived biomarker profile develops a multi-protein classifier in liquid biopsies for early detection of esophageal squamous cell carcinoma from a population-based case-control study. <i>Biomarker Research</i> , 2021, 9, 12.	2.8	7
779	A New Era of Protein-Based Assays for Cancer Early Detection. <i>Journal of Thoracic Oncology</i> , 2021, 16, 191-193.	0.5	1
780	Ovarian Cancer: Molecular Classification and Targeted Therapy. , 0, , .		4
782	Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine. <i>Cancers</i> , 2021, 13, 728.	1.7	19
783	Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 622459.	1.8	31
784	Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer. <i>Molecular Cancer</i> , 2021, 20, 36.	7.9	30

#	ARTICLE	IF	CITATIONS
785	Investigating Complex Samples with Molograms of Low-Affinity Binders. <i>ACS Sensors</i> , 2021, 6, 1067-1076.	4.0	5
786	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. <i>Cancers</i> , 2021, 13, 659.	1.7	25
787	High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition/mass spectrometry (HIA-DIA). <i>Proteomics</i> , 2021, 21, e2000264.	1.3	9
788	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 994.	1.7	29
789	Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention. <i>International Journal of Cancer</i> , 2021, 148, 3086-3096.	2.3	1
790	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	1.4	68
791	Opto-Thermophoretic Manipulation. <i>ACS Nano</i> , 2021, 15, 5925-5943.	7.3	59
792	Clinical application of circulating tumor DNA in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1431-1442.	1.2	5
794	Early detection of gastric cancer beyond endoscopy - new methods. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101731.	1.0	20
795	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , 2021, 16, 309-324.	1.7	14
797	A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk. <i>Scientific Reports</i> , 2021, 11, 5151.	1.6	14
799	Perspectives for the analysis of circulating tumor DNA in clinical oncology: achievements and unresolved issues. <i>Voprosy Onkologii</i> , 2021, 67, 29-34.	0.1	0
800	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021, 5, 1095-1105.	2.0	7
802	Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. <i>Clinical Cancer Research</i> , 2021, 27, 2592-2603.	3.2	14
803	Artificial Intelligence and Early Detection of Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 251-279.	0.5	71
804	Exploring Volatile Organic Compounds in Breath for High-Accuracy Prediction of Lung Cancer. <i>Cancers</i> , 2021, 13, 1431.	1.7	34
805	The Roadmap of Colorectal Cancer Screening. <i>Cancers</i> , 2021, 13, 1101.	1.7	28
806	Characterization of Cell Free Plasma Methyl-DNA From Xenografted Tumors to Guide the Selection of Diagnostic Markers for Early-Stage Cancers. <i>Frontiers in Oncology</i> , 2021, 11, .	1.3	2

#	ARTICLE	IF	CITATIONS
807	Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. <i>Hpb</i> , 2021, 23, 468-474.	0.1	6
808	Attomolar-Level Ultrasensitive and Multiplex microRNA Detection Enabled by a Nanomaterial Locally Assembled Microfluidic Biochip for Cancer Diagnosis. <i>Analytical Chemistry</i> , 2021, 93, 5129-5136.	3.2	44
809	The Emerging Role of Extracellular Vesicles in Endocrine Resistant Breast Cancer. <i>Cancers</i> , 2021, 13, 1160.	1.7	10
810	Plasmonic Alloys Reveal a Distinct Metabolic Phenotype of Early Gastric Cancer. <i>Advanced Materials</i> , 2021, 33, e2007978.	11.1	103
811	Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes. <i>Npj Precision Oncology</i> , 2021, 5, 25.	2.3	14
812	Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 583714.	1.3	9
813	Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 299-310.	1.5	23
814	Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. <i>Frontiers in Veterinary Science</i> , 2021, 8, 664718.	0.9	21
815	Optimization of blood handling for plasma extracellular vesicle isolation. <i>Journal of Nanoparticle Research</i> , 2021, 23, 1.	0.8	1
816	Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. <i>Pancreatology</i> , 2021, 21, 363-378.	0.5	32
817	Microfluidics for Liquid Biopsies: Recent Advances, Current Challenges, and Future Directions. <i>Analytical Chemistry</i> , 2021, 93, 4727-4738.	3.2	41
818	Combining Serum DNA Methylation Biomarkers and Protein Tumor Markers Improved Clinical Sensitivity for Early Detection of Colorectal Cancer. <i>International Journal of Genomics</i> , 2021, 2021, 1-11.	0.8	5
820	Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 685-695.	1.2	5
821	Exosome-based liquid biopsies in cancer: opportunities and challenges. <i>Annals of Oncology</i> , 2021, 32, 466-477.	0.6	405
822	Liquid Biopsy: From Discovery to Clinical Application. <i>Cancer Discovery</i> , 2021, 11, 858-873.	7.7	407
823	Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. <i>Nature Biotechnology</i> , 2021, 39, 1115-1128.	9.4	126
824	Artificial intelligence in oncology: From bench to clinic. <i>Seminars in Cancer Biology</i> , 2022, 84, 113-128.	4.3	16
825	The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 634316.	1.3	50

#	ARTICLE	IF	CITATIONS
826	Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review. <i>Cancers</i> , 2021, 13, 1820.	1.7	30
827	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1353-1361.	1.4	25
828	Noninvasive early diagnosis of intestinal diseases based on artificial intelligence in genomics and microbiome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 823-831.	1.4	13
829	A multiparametric extraction method for Vn96-isolated plasma extracellular vesicles and cell-free DNA that enables multi-omic profiling. <i>Scientific Reports</i> , 2021, 11, 8085.	1.6	8
830	Integral Multielement Signals by DNA-Programmed UCNP@AuNP Nanosatellite Assemblies for Ultrasensitive ICP-MS Detection of Exosomal Proteins and Cancer Identification. <i>Analytical Chemistry</i> , 2021, 93, 6437-6445.	3.2	48
831	The Detection of Cancer Epigenetic Traces in Cell-Free DNA. <i>Frontiers in Oncology</i> , 2021, 11, 662094.	1.3	4
833	Recognising Colorectal Cancer in Primary Care. <i>Advances in Therapy</i> , 2021, 38, 2732-2746.	1.3	10
834	In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0250717.	1.1	5
835	Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level. <i>Cancer Science</i> , 2021, 112, 2006-2019.	1.7	7
837	Role of Circulating Tumor DNA in Hematological Malignancy. <i>Cancers</i> , 2021, 13, 2078.	1.7	11
838	Liquid biopsy in NSCLC: a new challenge in radiation therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	0
839	Editorial: Non-invasive Technology Advances in Oncology. <i>Frontiers in Digital Health</i> , 2021, 3, 676216.	1.5	0
841	Values of liquid biopsy in early detection of cancer: results from meta-analysis. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 417-427.	1.5	5
842	Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges. <i>Cancers</i> , 2021, 13, 1874.	1.7	32
843	Current status of ctDNA in precision oncology for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 140.	3.5	15
844	How to use liquid biopsies to treat patients with cancer. <i>ESMO Open</i> , 2021, 6, 100060.	2.0	43
845	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021, 13, 1861.	1.7	4
847	Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low-Dose Computed Tomography. <i>Frontiers in Oncology</i> , 2021, 11, 555331.	1.3	10

#	ARTICLE	IF	CITATIONS
848	Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	11
849	Artificial Intelligence in Cancer Research and Precision Medicine. <i>Cancer Discovery</i> , 2021, 11, 900-915.	7.7	209
850	Rapid Discrimination of Extracellular Vesicles by Shape Distribution Analysis. <i>Analytical Chemistry</i> , 2021, 93, 7037-7044.	3.2	15
852	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , 2021, 13, 2274.	1.7	21
853	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. <i>Diagnostics</i> , 2021, 11, 999.	1.3	8
854	Cancer as a form of life: Musings of the cancer and evolution symposium. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 120-139.	1.4	6
855	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. <i>Nature Communications</i> , 2021, 12, 3230.	5.8	95
856	Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review. <i>Cancers</i> , 2021, 13, 2722.	1.7	22
857	Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook. <i>Molecular Oncology</i> , 2021, 15, 1683-1700.	2.1	43
859	Development of nanosensor by bioorthogonal reaction for multi-detection of the biomarkers of hepatocellular carcinoma. <i>Sensors and Actuators B: Chemical</i> , 2021, 334, 129653.	4.0	20
860	Caenorhabditis elegans as a Diagnostic Aid for Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 673-678.	0.5	6
861	Circular RNAs Are Promising Biomarkers in Liquid Biopsy for the Diagnosis of Non-small Cell Lung Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 625722.	1.6	18
862	Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. <i>Frontiers in Oncology</i> , 2021, 11, 639675.	1.3	3
863	Diagnostic value of combining tumor and inflammatory biomarkers in detecting common cancers in Korea. <i>Clinica Chimica Acta</i> , 2021, 516, 169-178.	0.5	5
864	Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. <i>Molecular Oncology</i> , 2021, 15, 1667-1682.	2.1	20
865	Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 2536.	5.8	147
866	Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing. <i>Nature Biomedical Engineering</i> , 2021, 5, 690-701.	11.6	27
867	Molecular approaches to lung cancer prevention. <i>Future Oncology</i> , 2021, 17, 1793-1810.	1.1	3

#	ARTICLE	IF	CITATIONS
868	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	3.6	26
869	Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2021, 96, 102193.	3.4	36
870	Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 616209.	1.3	13
871	The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5601.	1.8	22
872	Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 493-502.	8.2	370
873	Liquid biopsy & surgery: What's ahead?. <i>American Journal of Surgery</i> , 2021, , .	0.9	1
874	TP53 Targeted Deep Sequencing of Cell-Free DNA in Esophageal Squamous Cell Carcinoma Using Low-Quality Serum: Concordance with Tumor Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5627.	1.8	6
875	Artificial intelligence in oncology: Path to implementation. <i>Cancer Medicine</i> , 2021, 10, 4138-4149.	1.3	58
876	Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 2236.	1.0	4
877	Integration of Surface-enhanced Raman Spectroscopy with <i>PCR</i> for Monitoring Single Copy of <i>KRAS G12D</i> Mutation. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 945-951.	1.0	3
878	Early Diagnosis and Screening for Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037994.	2.9	13
879	Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103311.	2.0	24
880	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
882	Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2248.	1.0	12
884	Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 389-408.	1.6	26
885	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. <i>Nature Biotechnology</i> , 2021, 39, 1220-1227.	9.4	40
886	A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules. <i>Advanced Science</i> , 2021, 8, 2100104.	5.6	10
887	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 89.	3.6	10

#	ARTICLE	IF	CITATIONS
888	The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 780-788.	2.9	10
889	A DNA methylation-based liquid biopsy for triple-negative breast cancer. <i>Npj Precision Oncology</i> , 2021, 5, 53.	2.3	11
890	Machine Learning Protocols in Early Cancer Detection Based on Liquid Biopsy: A Survey. <i>Life</i> , 2021, 11, 638.	1.1	28
891	Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. <i>Gynecologic Oncology</i> , 2021, 161, 884-895.	0.6	12
892	Nanozyme Sensor Array Plus Solvent-Mediated Signal Amplification Strategy for Ultrasensitive Ratiometric Fluorescence Detection of Exosomal Proteins and Cancer Identification. <i>Analytical Chemistry</i> , 2021, 93, 9002-9010.	3.2	61
893	Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 13263.	1.6	1
894	Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. <i>Nature Biomedical Engineering</i> , 2021, 5, 586-599.	11.6	74
896	Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes. , 0, , .		0
898	Confirming putative variants at a 5% allele frequency using allele enrichment and Sanger sequencing. <i>Scientific Reports</i> , 2021, 11, 11640.	1.6	20
899	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. <i>Cancers</i> , 2021, 13, 3002.	1.7	15
900	HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. <i>ESMO Open</i> , 2021, 6, 100154.	2.0	30
901	Early detection of pancreatic cancer using DNA-based molecular approaches. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 457-468.	8.2	67
902	Clinical implementation and current advancement of blood liquid biopsy in cancer. <i>Journal of Human Genetics</i> , 2021, 66, 909-926.	1.1	16
903	Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 122-132.	1.4	9
904	AI in Measurement Science. <i>Annual Review of Analytical Chemistry</i> , 2021, 14, 1-19.	2.8	11
905	Using Risk Stratification to Optimize Mammography Screening in Chinese Women. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab060.	1.4	0
906	Targeted silencing of TEM8 suppresses non-small cell lung cancer tumor growth via the ERK/Bcl-2 signaling pathway. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	4
907	Fluorescence Liquid Biopsy for Cancer Detection Is Improved by Using Cationic Dendronized Hyperbranched Polymer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6501.	1.8	4

#	ARTICLE	IF	CITATIONS
908	imPlatelet classifier: image-converted RNA biomarker profiles enable blood-based cancer diagnostics. <i>Molecular Oncology</i> , 2021, 15, 2688-2701.	2.1	16
909	Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data. <i>PLoS ONE</i> , 2021, 16, e0251876.	1.1	27
910	Association of Breast Cancer Screening Behaviors With Stage at Breast Cancer Diagnosis and Potential for Additive Multi-Cancer Detection via Liquid Biopsy Screening: A Claims-Based Study. <i>Frontiers in Oncology</i> , 2021, 11, 688455.	1.3	4
911	Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. <i>Cancers</i> , 2021, 13, 3522.	1.7	4
912	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. <i>Engineering</i> , 2021, 7, 1369-1369.	3.2	1
913	Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3457-3472.	1.3	1
914	Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA. <i>Frontiers in Genetics</i> , 2021, 12, 671057.	1.1	22
915	Microenvironment-triggered multimodal precision diagnostics. <i>Nature Materials</i> , 2021, 20, 1440-1448.	13.3	42
917	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021, 13, 3501.	1.7	50
918	Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. <i>Cancers</i> , 2021, 13, 3793.	1.7	19
919	Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200294.	3.0	7
920	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	6.1	24
921	Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2021, 156, 663.	2.2	30
922	Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12121.	5.5	18
923	A deep learning model for predicting next-generation sequencing depth from DNA sequence. <i>Nature Communications</i> , 2021, 12, 4387.	5.8	26
924	Future Screening Prospects for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3840.	1.7	21
925	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101766.	0.7	0
926	Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7411.	1.8	3

#	ARTICLE	IF	CITATIONS
927	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3656.	1.7	8
928	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. <i>Cancers</i> , 2021, 13, 3600.	1.7	37
929	Blood-Based Liquid Biopsy for Comprehensive Cancer Genomic Profiling Using Next-Generation Sequencing: An Emerging Paradigm for Non-invasive Cancer Detection and Management in Dogs. <i>Frontiers in Veterinary Science</i> , 2021, 8, 704835.	0.9	13
930	Characterization of DNA lesions associated with cell-free DNA by targeted deep sequencing. <i>BMC Medical Genomics</i> , 2021, 14, 192.	0.7	3
931	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	5.8	16
932	Rapid Spectroscopic Liquid Biopsy for the Universal Detection of Brain Tumours. <i>Cancers</i> , 2021, 13, 3851.	1.7	22
933	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, e1812-e1821.	1.9	15
934	Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results. <i>Cancers</i> , 2021, 13, 4104.	1.7	9
935	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. <i>Cancer Biology and Therapy</i> , 2021, 22, 455-464.	1.5	6
936	Plasma Based Protein Signatures Associated with Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3972.	1.7	2
937	Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection. <i>PLoS ONE</i> , 2021, 16, e0255804.	1.1	11
938	Alu cell-free DNA concentration, Alu index, and LINE-1 hypomethylation as a cancer predictor. <i>Clinical Biochemistry</i> , 2021, 94, 67-73.	0.8	9
939	Biomarkers and Lung Cancer Early Detection: State of the Art. <i>Cancers</i> , 2021, 13, 3919.	1.7	31
940	The Extracellular Metabolome Stratifies Low and High Risk Potentially Premalignant Oral Keratinocytes and Identifies Citrate as a Potential Non-Invasive Marker of Tumour Progression. <i>Cancers</i> , 2021, 13, 4212.	1.7	4
941	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , 2021, 13, 4334.	1.7	20
942	Cancer cells are highly susceptible to accumulation of templated insertions linked to MMBIR. <i>Nucleic Acids Research</i> , 2021, 49, 8714-8731.	6.5	12
943	Protein detection in blood with single-molecule imaging. <i>Science Advances</i> , 2021, 7, .	4.7	15
944	Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 725938.	1.3	20

#	ARTICLE	IF	CITATIONS
945	Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. <i>Clinical Chemistry</i> , 2022, 68, 344-353.	1.5	5
946	CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection. <i>Analytical Chemistry</i> , 2021, 93, 11899-11909.	3.2	54
947	Using cell-free DNA for HCC surveillance and prognosis. <i>JHEP Reports</i> , 2021, 3, 100304.	2.6	27
949	Nanotechnology in Tumor Biomarker Detection: The Potential of Liganded Nanoclusters as Nonlinear Optical Contrast Agents for Molecular Diagnostics of Cancer. <i>Cancers</i> , 2021, 13, 4206.	1.7	27
950	Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 86.	1.3	10
951	Clinical correlates of circulating cell-free DNA tumor fraction. <i>PLoS ONE</i> , 2021, 16, e0256436.	1.1	32
952	Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. <i>PLoS Medicine</i> , 2021, 18, e1003734.	3.9	35
953	Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. <i>Journal of Molecular Pathology</i> , 2021, 2, 255-273.	0.5	18
954	Cancer evolution: Darwin and beyond. <i>EMBO Journal</i> , 2021, 40, e108389.	3.5	118
955	Multicancer Early Detection: Learning From the Past to Meet the Future. <i>Journal of the National Cancer Institute</i> , 2022, 114, 349-352.	3.0	22
956	Liquid Biopsy, ctDNA Diagnosis through NGS. <i>Life</i> , 2021, 11, 890.	1.1	36
957	Risk-Predictive and Diagnostic Biomarkers for Colorectal Cancer; a Systematic Review of Studies Using Pre-Diagnostic Blood Samples Collected in Prospective Cohorts and Screening Settings. <i>Cancers</i> , 2021, 13, 4406.	1.7	14
958	EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 6135-6144.	3.2	26
959	α 26-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00395.	1.3	9
960	Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. <i>Gut</i> , 2022, 71, 1315-1325.	6.1	97
961	Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal. <i>Cancer Genetics</i> , 2021, 256-257, 165-178.	0.2	5
962	Building Personalized Cancer Therapeutics through Multi-Omics Assays and Bacteriophage-Eukaryotic Cell Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9712.	1.8	2
963	Noninvasive prenatal testing: Advancing through a virtuous circle of science, technology and clinical applications. <i>Prenatal Diagnosis</i> , 2021, 41, 1190-1192.	1.1	4

#	ARTICLE	IF	CITATIONS
964	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. <i>Npj Precision Oncology</i> , 2021, 5, 83.	2.3	4
965	Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma. <i>Epigenomes</i> , 2021, 5, 20.	0.8	3
966	Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 754094.	1.3	5
967	High-throughput proteomics and AI for cancer biomarker discovery. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113844.	6.6	54
968	Early detection of pancreatic cancer: current state and future opportunities. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 532-538.	1.0	6
969	Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α -Fetoprotein. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1174-1184.	1.2	14
970	Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?. <i>Seminars in Cancer Biology</i> , 2021, 74, 105-120.	4.3	36
971	Recent Advances in Pediatric Cancer Research. <i>Cancer Research</i> , 2021, 81, 5783-5799.	0.4	8
973	Circulating Tumor DNA in Lymphoma: Principles and Future Directions. <i>Blood Cancer Discovery</i> , 2022, 3, 5-15.	2.6	25
975	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4500.	1.7	11
976	A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 38-44.	1.1	8
977	Metabolomics as a Tool for Biomarker Discovery in Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1601-1603.	1.1	0
978	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. <i>Cancers</i> , 2021, 13, 4803.	1.7	6
979	Synthetic biomarkers: a twenty-first century path to early cancer detection. <i>Nature Reviews Cancer</i> , 2021, 21, 655-668.	12.8	84
980	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	2.1	7
981	Protocell arrays for simultaneous detection of diverse analytes. <i>Nature Communications</i> , 2021, 12, 5724.	5.8	18
982	Porous Inorganic Materials for Bioanalysis and Diagnostic Applications. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 4092-4109.	2.6	11
983	Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?. <i>World Journal of Gastroenterology</i> , 2021, 27, 5536-5554.	1.4	6

#	ARTICLE	IF	CITATIONS
984	Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 736330.	1.6	10
985	Current Trends in Cell-Free DNA Applications. Scoping Review of Clinical Trials. <i>Biology</i> , 2021, 10, 906.	1.3	12
986	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021, 7, eabh0534.	4.7	41
987	A fatal affair: Circulating tumor cell relationships that shape metastasis. <i>IScience</i> , 2021, 24, 103073.	1.9	8
988	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. <i>Genome Biology</i> , 2021, 22, 227.	3.8	13
990	Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. <i>Annals of Oncology</i> , 2021, 32, 1167-1177.	0.6	363
991	Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. <i>Obesity Reviews</i> , 2022, 23, e13358.	3.1	20
992	Aptamer-decorated porous microneedles arrays for extraction and detection of skin interstitial fluid biomarkers. <i>Biosensors and Bioelectronics</i> , 2021, 190, 113404.	5.3	43
993	Inherited Pancreatic Cancer Syndromes and High-Risk Screening. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 773-786.	0.6	16
994	Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist. <i>Radiographics</i> , 2021, 41, 1839-1856.	1.4	10
995	Circulating tumour DNA for clinicians: current and future clinical applications. <i>Clinical Radiology</i> , 2021, 76, 737-747.	0.5	2
996	Ultrasensitive SQDs-based electrochemiluminescence assay for determination of miRNA-141 with dual-amplification of co-reaction accelerators and DNA walker. <i>Sensors and Actuators B: Chemical</i> , 2021, 345, 130405.	4.0	22
997	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	0.5	274
998	Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 963-971.	0.9	22
999	Invited Commentary: Imaging in the Context of Serum Tumor Markers—Where Are We Headed?. <i>Radiographics</i> , 2021, 41, E181-E182.	1.4	0
1000	Machine Learning of Serum Metabolic Patterns Encodes Asymptomatic SARS-CoV-2 Infection. <i>Frontiers in Chemistry</i> , 2021, 9, 746134.	1.8	5
1001	Recent progress in the development of aptasensors for cancer diagnosis: Focusing on aptamers against cancer biomarkers. <i>Microchemical Journal</i> , 2021, 170, 106640.	2.3	13
1002	Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. <i>Cancer Letters</i> , 2021, 520, 1-11.	3.2	128

#	ARTICLE	IF	CITATIONS
1003	Biomarkers associated with different types of cancer as a potential candidate for early diagnosis of oncological disorders. , 2022, , 47-57.		8
1004	Pulmonary Nodules. , 2022, , 679-696.		0
1005	Recent advances of emerging microfluidic chips for exosome mediated cancer diagnosis. Smart Materials in Medicine, 2021, 2, 158-171.	3.7	13
1006	Liquid Biopsy. , 2021, , 377-394.		0
1007	Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients. Clinical Chemistry, 2022, 68, 354-364.	1.5	18
1008	Biomarkers in Pancreatic Cancer. , 2021, , 467-487.		1
1009	Targeting metastatic cancer. Nature Medicine, 2021, 27, 34-44.	15.2	447
1010	Detection of acquired radioresistance in breast cancer cell lines using Raman spectroscopy and machine learning. Analyst, The, 2021, 146, 3709-3716.	1.7	4
1012	Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics. Clinical Proteomics, 2021, 18, 4.	1.1	11
1013	Longitudinal analysis of cell-free mutated KRAS and CA 19â€“9 predicts survival following curative resection of pancreatic cancer. BMC Cancer, 2021, 21, 49.	1.1	19
1014	Biomarkers in lung cancer screening: the importance of study design. European Respiratory Journal, 2021, 57, 2004367.	3.1	3
1015	Evolutionary model of brain tumor circulating cells: Cellular galaxy. World Journal of Clinical Oncology, 2021, 12, 13-30.	0.9	5
1016	A 3-Decade Analysis of Pancreatic Adenocarcinoma After Solid Organ Transplant. Pancreas, 2021, 50, 54-63.	0.5	4
1017	Association of the Neutrophil Extracellular Traps Formation With the Production of Circulating Cell-Free DNA and Anti-Cardiolipin Autoantibody in Patients With a Metastatic Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	2
1018	Toward a Liquid Biopsy: Greedy Approximation Algorithmsfor Active Sequential Hypothesis Testing. SSRN Electronic Journal, 0, , .	0.4	1
1019	CancerEMC: frontline non-invasive cancer screening from circulating protein biomarkers and mutations in cell-free DNA. Bioinformatics, 2021, 37, 3319-3327.	1.8	2
1021	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. Recent Results in Cancer Research, 2020, 215, 213-230.	1.8	15
1022	Cell-Free DNA in the Management of Colorectal Cancer. Recent Results in Cancer Research, 2020, 215, 253-261.	1.8	5

#	ARTICLE	IF	CITATIONS
1023	Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. <i>Recent Results in Cancer Research</i> , 2020, 215, 163-180.	1.8	26
1024	Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.		13
1025	Salivaomics, Saliva-Exosomics, and Saliva Liquid Biopsy. , 2020, , 157-175.		5
1026	Cancer Genomics in Precision Oncology: Applications, Challenges, and Prospects. , 2020, , 453-499.		9
1027	Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 2170-2174.	1.2	9
1028	Liquid biopsy in ovarian cancer. <i>Advances in Clinical Chemistry</i> , 2020, 97, 13-71.	1.8	9
1029	Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. <i>Trends in Molecular Medicine</i> , 2020, 26, 519-528.	3.5	151
1030	Direct Kinetic Fingerprinting for High-Accuracy Single-Molecule Counting of Diverse Disease Biomarkers. <i>Accounts of Chemical Research</i> , 2021, 54, 388-402.	7.6	30
1031	Could liquid biopsies help deliver better treatment?. <i>Nature</i> , 2020, 579, S6-S8.	13.7	9
1032	The future of liquid biopsy. <i>Nature</i> , 2020, 579, S9-S9.	13.7	110
1033	Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer. <i>Scientific Reports</i> , 2020, 10, 1451.	1.6	39
1034	Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis. <i>Scientific Reports</i> , 2020, 10, 16275.	1.6	12
1035	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
1050	Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring. <i>Cancer Research</i> , 2018, 78, 3407-3412.	0.4	188
1051	Mosaic-variegated aneuploidy syndrome mutation or haploinsufficiency in Cep57 impairs tumor suppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 3517-3534.	3.9	17
1052	Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12021-12021.	0.8	50
1053	NGS-PrimerPlex: High-throughput primer design for multiplex polymerase chain reactions. <i>PLoS Computational Biology</i> , 2020, 16, e1008468.	1.5	11
1054	Hepatocellular Carcinoma Surveillance and Treatment: A Way to Reduce Cancer-related Mortality in Cirrhotic Patients. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-2.	0.7	17

#	ARTICLE	IF	CITATIONS
1055	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	15
1056	Glycan-specific antibodies as potential cancer biomarkers: a focus on microarray applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1611-1622.	1.4	15
1057	Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 19356-19367.	0.8	17
1058	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	0.8	15
1059	The use of cell free DNA in the diagnosis of HCC. <i>Hepatoma Research</i> , 2019, 2019, .	0.6	11
1060	Future perspectives from lung cancer pre-clinical models: new treatments are coming?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2629-2644.	1.3	3
1061	Rezidiv ve Metastaz Tespiti İçin Bir Sıvı Biyopsi Yöntemi Olarak Alelspesifik Emilimsiyon PCR (asePCR). <i>Anadolu Kliniği Tıp Bilimleri Dergisi</i> , 2019, 24, 47-52.	0.1	5
1062	Cancer Biomarker Discovery for Precision Medicine: New Progress. <i>Current Medicinal Chemistry</i> , 2020, 26, 7655-7671.	1.2	51
1063	A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study. <i>JMIR Medical Informatics</i> , 2019, 7, e13476.	1.3	24
1064	Early-onset colorectal cancer research: gaps and opportunities. <i>Colorectal Cancer</i> , 2020, 9, CRC34.	0.8	9
1065	Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA. <i>Neurosurgical Focus</i> , 2020, 48, E9.	1.0	36
1066	Non-invasive Molecular Detection of Minimal Residual Disease in Papillary Thyroid Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1510.	1.3	9
1067	Non-Invasive Biomarkers for Early Detection of Breast Cancer. <i>Cancers</i> , 2020, 12, 2767.	1.7	106
1068	Oral microbiome and pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 7679-7692.	1.4	44
1069	Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy. <i>Beilstein Journal of Nanotechnology</i> , 2020, 11, 263-284.	1.5	9
1071	Emerging non-invasive detection methodologies for lung cancer (Review). <i>Oncology Letters</i> , 2020, 19, 3389-3399.	0.8	7
1072	Cell-free DNA as a liquid biopsy for early detection of gastric cancer (Review). <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	18
1073	Intraductal papillary mucinous neoplasm to pancreas ductal adenocarcinoma sequence and pancreas cancer screening. <i>Endoscopic Ultrasound</i> , 2018, 7, 314.	0.6	10

#	ARTICLE	IF	CITATIONS
1074	Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 779-788.	1.3	24
1075	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 12, 1-20.	0.8	31
1076	Donor-specific cell-free DNA as a biomarker in liver transplantation: A review. <i>World Journal of Transplantation</i> , 2020, 10, 307-319.	0.6	18
1077	Liquid Biopsy in Breast Cancer: A Focused Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 678-686.	1.2	64
1078	In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta. <i>ELife</i> , 2019, 8, .	2.8	56
1079	Liquid Biopsy. <i>UNIPA Springer Series</i> , 2021, , 99-122.	0.1	0
1080	An Isogenic Cell Line Panel for Sequence-Based Screening of Targeted Anti-Cancer Drugs. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1081	Recent advances in waste-recycled nanomaterials for biomedical applications: Waste-to-wealth. <i>Nanotechnology Reviews</i> , 2021, 10, 1662-1739.	2.6	50
1082	Platelet RNA Signature Enables Early and Accurate Detection of Ovarian Cancer: An Intercontinental, Biomarker Identification Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1083	Integrity of cell-free DNA in maternal plasma extracellular vesicles as a potential biomarker for non-invasive prenatal testing. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 158, 406-417.	1.0	4
1084	Precision diagnostics: Integration of tissue pathology and genomics in cancer. <i>Pathology</i> , 2021, 53, 809-817.	0.3	2
1085	Liquid Biopsies for Molecular Biology-Based Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11267.	1.8	4
1086	Molecular testing for colorectal cancer: Clinical applications. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1288-1301.	0.8	9
1087	A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab081.	1.4	10
1088	Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients. <i>Cancer Medicine</i> , 2021, 10, 8377-8386.	1.3	7
1089	Biomarkers for Gastric Cancer Screening and Early Diagnosis. <i>Biomedicines</i> , 2021, 9, 1448.	1.4	29
1090	Complex Age- and Cancer-Related Changes in Human Blood Transcriptome—Implications for Pan-Cancer Diagnostics. <i>Frontiers in Genetics</i> , 2021, 12, 746879.	1.1	7
1091	BH-index: A predictive system based on serum biomarkers and ensemble learning for early colorectal cancer diagnosis in mass screening. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 212, 106494.	2.6	3

#	ARTICLE	IF	CITATIONS
1092	Liquid biopsy approach to pancreatic cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 1263-1287.	0.8	7
1093	Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls. Scientific Reports, 2021, 11, 20322.	1.6	17
1094	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. Med, 2021, 2, 1171-1193.e11.	2.2	24
1095	A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA. Scientific Reports, 2021, 11, 19653.	1.6	7
1096	Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Communications, 2021, 41, 1100-1115.	3.7	71
1097	Next steps in the early detection of ovarian cancer. Communications Medicine, 2021, 1, .	1.9	16
1098	Refining a Postpandemic Approach to Cancer Screening. Journal of Patient-centered Research and Reviews, 2021, 8, 295-296.	0.6	0
1099	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. Thoracic Surgery Clinics, 2021, 31, 399-406.	0.4	1
1100	Cell-free Nucleic Acids in Cancer. Advances in Molecular Pathology, 2021, 4, 187-198.	0.2	1
1102	Simple blood test detects eight different kinds of cancer. Nature, 0, , .	13.7	0
1103	Biomarker for the Treatment of Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 425-434.	0.1	0
1105	Cancer Precision Medicine; Where We Should Go?. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1688-1695.	0.0	0
1108	Clinical and Prognostic Value of Molecular Markers of Diffuse Large B-Cell Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 95-100.	0.1	4
1109	Liquid biopsies in myeloid malignancies. , 2019, 2, 1044-1061.		5
1110	The New Bench for the Academic Surgeon: Precision Medicine. , 2019, , 187-198.		0
1111	Lung Cancer Prevention. , 2019, , 511-542.		0
1114	Biopsia liquida: una review. Rivista Italiana Della Medicina Di Laboratorio, 2019, 15, .	0.2	0
1117	Les nouveaux outils biologiques pour améliorer le dépistage du cancer bronchique. Revue Des Maladies Respiratoires Actualites, 2019, 11, 200-206.	0.0	0

#	ARTICLE	IF	CITATIONS
1118	Just caring: screening needs limits. <i>Journal of Medical Ethics</i> , 2020, 46, 253-254.	1.0	0
1119	Liquid Biopsy Diagnosis of CNS Metastases. , 2020, , 73-86.		0
1120	Gene selection ensembles and classifier ensembles for medical diagnosis. <i>Biometrical Letters</i> , 2019, 56, 117-138.	0.4	0
1121	Liquid Biopsy to Characterize Cell-Free DNA in Cancer Detection and Monitoring. <i>Research and Development on Information and Communication Technology</i> , 2019, 2019, 93-98.	0.4	0
1122	Hepatocyte Growth Factor and Macrophage-stimulating Protein α -Hinge-Analogs to Treat Pancreatic Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 782-795.	0.8	1
1123	The association between diabetes and cancer in Mexico: Analysis using death certificate databases, 2009-2017. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1397.	0.3	2
1126	La biopsia líquida en el manejo del cáncer: una nueva herramienta revolucionaria de la medicina de precisión, aún con limitaciones. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
1131	Liquid biopsy of pancreatic tumors: Challenges for early detection and surveillance based on the molecular landscape during early carcinogenesis. <i>Suizo</i> , 2020, 35, 302-312.	0.1	2
1132	Breast cancer glycan biomarkers: their link to tumour cell metabolism and their perspectives in clinical practice. <i>Expert Review of Proteomics</i> , 2021, 18, 881-910.	1.3	5
1133	Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 757-774.	1.6	16
1134	Using artificial intelligence in a primary care setting to identify patients at risk for cancer: a risk prediction model based on routine laboratory tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 2005-2016.	1.4	11
1136	Enhanced Detection of Genitourinary Cancers Using Fragmentation and Copy Number Profiles Obtained from Urinary Cell-Free DNA. <i>Clinical Chemistry</i> , 2021, 67, 394-403.	1.5	5
1137	Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 17-17.	1.2	5
1138	An Overview of Promising Biomarkers in Cancer Screening and Detection. <i>Current Cancer Drug Targets</i> , 2020, 20, 831-852.	0.8	1
1139	Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. , 2022, , 207-230.		0
1140	Circulating RNAs in prostate cancer patients. <i>Cancer Letters</i> , 2022, 524, 57-69.	3.2	39
1141	Incorporating Circulating Biomarkers into Clinical Trials. , 2020, , 233-247.		0
1142	Introduction to this Special Issue: α -Biomarker Discovery and Precision Medicine. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.5	0

#	ARTICLE	IF	CITATIONS
1143	Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study. SSRN Electronic Journal, 0, , .	0.4	0
1144	Circulating Tumor DNA as a Novel Biomarker for Pancreatic Cancer. Molecular and Translational Medicine, 2020, , 107-116.	0.4	0
1145	Precision medicine in the genomic era. , 2020, , 445-452.		0
1146	Circulating Tumor Cells as Biomarkers in Pancreatic Cancer. Molecular and Translational Medicine, 2020, , 129-143.	0.4	0
1148	The contribution of the 20th century discoveries on the circulating DNA as biomarkers for cancer screening. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20200919.	0.3	2
1149	Machine intelligence in non-invasive endocrine cancer diagnostics. Nature Reviews Endocrinology, 2022, 18, 81-95.	4.3	25
1150	The Role and Impact of Minimal Residual Disease in NSCLC. Current Oncology Reports, 2021, 23, 136.	1.8	13
1151	Future Directions in Artificial Intelligence. Radiologic Clinics of North America, 2021, 59, 1085-1095.	0.9	6
1152	Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037812.	2.9	8
1154	Strategies to Improve Persistent Adherence in Colorectal Cancer Screening. Gut and Liver, 2020, 14, 546-552.	1.4	9
1157	Multiplexed Protein Biomarker Detection with Microfluidic Electrochemical Immunoarrays. Methods in Molecular Biology, 2021, 2237, 69-82.	0.4	2
1158	Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World Journal of Clinical Oncology, 2020, 11, 868-889.	0.9	17
1159	Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 441-449.	1.1	10
1160	Liquid Biopsy in the OMICS Era of Tumor Medicine. , 2018, 1, .		1
1161	Circulating tumor DNA in colorectal cancer: opportunities and challenges. American Journal of Translational Research (discontinued), 2020, 12, 1044-1055.	0.0	14
1163	Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. American Journal of Translational Research (discontinued), 2021, 13, 4489-4499.	0.0	3
1164	Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer. Iranian Journal of Medical Sciences, 2021, 46, 339-346.	0.3	0
1165	Highly Sensitive Detection Method of <i>DICER1</i> Tumor Hotspot Mutations by Drop-off Droplet Digital PCR. Clinical Chemistry, 2022, 68, 322-331.	1.5	4

#	ARTICLE	IF	CITATIONS
1166	Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals. , 2022, , 471-512.		0
1167	Pancreatic Cancer Surveillance and Novel Strategies for Screening. Gastrointestinal Endoscopy Clinics of North America, 2022, 32, 13-25.	0.6	4
1168	Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA. Theranostics, 2022, 12, 362-378.	4.6	21
1169	Evaluation of Diagnostic Performance of Machine Learning Algorithms to Classify the Fetal Heart Rate Baseline from Cardiotocograph. International Journal of Business Analytics, 2022, 9, 0-0.	0.2	1
1170	Application of Nanobiosensor in Health Care Sector. , 2022, , 251-270.		6
1171	Racial/ethnic differences in cancer diagnosed after metastasis: absolute burden and deaths potentially avoidable through earlier detection. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0823.2021.	1.1	7
1172	Nearâ€Infrared Multilayer MoS₂ Photoconductivityâ€Enabled Ultrasensitive Homogeneous Plasmonic Colorimetric Biosensing. Advanced Materials Interfaces, 2021, 8, .	1.9	3
1173	A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages. RNA Biology, 2021, 18, 747-756.	1.5	4
1174	Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. Clinical Proteomics, 2021, 18, 27.	1.1	9
1175	Liquid biopsies in pediatric oncology: opportunities and obstacles. Current Opinion in Pediatrics, 2022, 34, 39-47.	1.0	5
1176	Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics, 2021, 11, 2171.	1.3	26
1177	Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma. Nature Communications, 2021, 12, 6479.	5.8	43
1178	A Rapid and Facile Separationâ€Detection Integrated Strategy for Exosome Profiling Based on Boronic Acid-Directed Coupling Immunoaffinity. Analytical Chemistry, 2021, 93, 16059-16067.	3.2	9
1179	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776.	1.5	12
1180	Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reproductive Biology and Endocrinology, 2021, 19, 178.	1.4	17
1181	A Selected Deep Learning Cancer Prediction Framework. IEEE Access, 2021, 9, 151476-151492.	2.6	5
1182	Exploring the Ethics of Implementation of Epigenomics Technologies in Cancer Screening: A Focus Group Study. Epigenetics Insights, 2021, 14, 251686572110636.	0.6	3
1183	Novel omics technology driving translational research in precision oncology. Advances in Genetics, 2021, 108, 81-145.	0.8	3

#	ARTICLE	IF	CITATIONS
1184	The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer. <i>BMC Cancer</i> , 2022, 22, 12.	1.1	2
1185	Lipidomic profiling of human serum enables detection of pancreatic cancer. <i>Nature Communications</i> , 2022, 13, 124.	5.8	68
1186	Advances in quantifying circulatory microRNA for early disease detection. <i>Current Opinion in Biotechnology</i> , 2022, 74, 256-262.	3.3	18
1188	Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologiesâ€œFrom Discovery to Knowledge-Guided Platforms for Better Patient Management. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 795735.	1.8	11
1189	Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs. <i>Cancers</i> , 2022, 14, 462.	1.7	16
1190	Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma. <i>BMC Medicine</i> , 2022, 20, 8.	2.3	23
1191	Noncoding RNAs and Deep Learning Neural Network Discriminate Multi-Cancer Types. <i>Cancers</i> , 2022, 14, 352.	1.7	5
1192	Using all our genomes: Bloodâ€based liquid biopsies for the early detection of cancer. <i>View</i> , 2022, 3, .	2.7	21
1194	Genomeâ€wide DNA methylation profiling and identification of potential panâ€cancer and tumorâ€specific biomarkers. <i>Molecular Oncology</i> , 2022, 16, 2432-2447.	2.1	9
1195	Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers. <i>Frontiers in Medicine</i> , 2021, 8, 772166.	1.2	6
1196	Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer. <i>iScience</i> , 2022, 25, 103826.	1.9	13
1197	Development and validation of a circulating microRNA panel for the early detection of breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 472-481.	2.9	21
1198	Diagnostic performance improvement with combined use of proteomics biomarker assay and breast ultrasound. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 541-552.	1.1	2
1199	Cancer outcome research â€œ a European challenge Part II: Opportunities and priorities. <i>Molecular Oncology</i> , 2022, 16, 2300-2311.	2.1	1
1200	Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification. <i>Journal of Translational Medicine</i> , 2022, 20, 18.	1.8	4
1201	Branched, dendritic, and hyperbranched polymers in liquid biopsy device design. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1770.	3.3	6
1202	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. <i>Nature Biomedical Engineering</i> , 2022, 6, 232-245.	11.6	56
1203	Recent advances in exosome analysis assisted by functional nucleic acid-based signal amplification technologies. <i>TrAC - Trends in Analytical Chemistry</i> , 2022, 149, 116549.	5.8	10

#	ARTICLE	IF	CITATIONS
1204	Quantification of human plasma metalloproteins in multiple sclerosis, ischemic stroke and healthy controls reveals an association of haptoglobin-hemoglobin complexes with age. PLoS ONE, 2022, 17, e0262160.	1.1	7
1205	Role of ctDNA in Breast Cancer. Cancers, 2022, 14, 310.	1.7	40
1206	Urine DNA biomarkers for hepatocellular carcinoma screening. British Journal of Cancer, 2022, 126, 1432-1438.	2.9	15
1209	Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening. British Journal of Cancer, 2022, , .	2.9	4
1210	Coding and regulatory variants are associated with serum protein levels and disease. Nature Communications, 2022, 13, 481.	5.8	18
1211	Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification. Nature Communications, 2022, 13, 617.	5.8	27
1212	Bioinformatics analysis methods for cell-free DNA. Computers in Biology and Medicine, 2022, 143, 105283.	3.9	3
1213	Liquid biopsy: the value of different bodily fluids. Biomarkers in Medicine, 2022, 16, 127-145.	0.6	12
1214	Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis. Science Translational Medicine, 2022, 14, eabk2756.	5.8	57
1215	Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer. Translational Oncology, 2022, 17, 101339.	1.7	1
1216	Carbon dots and Methylene blue facilitated photometric quantification of Hemoglobin. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 271, 120906.	2.0	6
1217	Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. Cancer Informatics, 2022, 21, 117693512210760.	0.9	27
1218	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. Breast Cancer Research and Treatment, 2022, 192, 465-484.	1.1	6
1219	Opportunities for Early Cancer Detection: The Rise of ctDNA Methylation-Based Pan-Cancer Screening Technologies. Epigenomes, 2022, 6, 6.	0.8	14
1220	Multicancer early detection test: Preclinical, translational, and clinical evidenceâ€“generation plan and provocative questions. Cancer, 2022, 128, 861-874.	2.0	7
1222	Patient engagement and advocacy considerations in development and implementation of a multicancer early detection program. Cancer, 2022, 128, 909-917.	2.0	1
1223	A non-invasive method for concurrent detection of early-stage women-specific cancers. Scientific Reports, 2022, 12, 2301.	1.6	10
1224	New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening. Cancer Cell, 2022, 40, 109-113.	7.7	35

#	ARTICLE	IF	CITATIONS
1243	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. <i>Diagnostics</i> , 2022, 12, 870.	1.3	18
1244	Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy. <i>Cancers</i> , 2022, 14, 1384.	1.7	33
1245	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 592-602.	2.9	36
1246	Individualized circulating tumor <scp>DNA</scp> monitoring in head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3960-3968.	1.3	15
1247	Cancer Stem Cell DNA Enabled Real-time Genotyping with Self-functionalized Quantum Superstructures Overcoming the Barriers of Noninvasive cfDNA Cancer Diagnostics. <i>Small Methods</i> , 2022, 6, e2101467.	4.6	1
1248	Field cancerization in breast cancer. <i>Journal of Pathology</i> , 2022, 257, 561-574.	2.1	16
1249	A clinician's handbook for using ctDNA throughout the patient journey. <i>Molecular Cancer</i> , 2022, 21, 81.	7.9	43
1250	Cancer Diagnostics and Early Detection Using Electrochemical Aptasensors. <i>Micromachines</i> , 2022, 13, 522.	1.4	14
1251	Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1757.	1.7	12
1252	Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 834992.	1.3	8
1253	A Novel Blood-Based microRNA Diagnostic Model with High Accuracy for Multi-Cancer Early Detection. <i>Cancers</i> , 2022, 14, 1450.	1.7	8
1254	Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. <i>Cancer Science</i> , 2022, 113, 2144-2166.	1.7	7
1255	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 394-407.	2.9	41
1256	Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	6
1257	Liquid Profiling for Cancer Patient Stratification in Precision Medicine Current Status and Challenges for Successful Implementation in Standard Care. <i>Diagnostics</i> , 2022, 12, 748.	1.3	9
1258	Potential of blood-based biomarker approaches in endometrium and breast cancer: a case-control comparison study. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1623-1632.	0.8	2
1259	The potential of liquid biopsy in the management of cancer patients. <i>Seminars in Cancer Biology</i> , 2022, 84, 69-79.	4.3	55
1260	The Role of Artificial Intelligence in Early Cancer Diagnosis. <i>Cancers</i> , 2022, 14, 1524.	1.7	71

#	ARTICLE	IF	CITATIONS
1261	Plasma Polyamine Biomarker Panels: Agmatine in Support of Prostate Cancer Diagnosis. <i>Biomolecules</i> , 2022, 12, 514.	1.8	9
1262	Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
1263	Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2022, 6, 17.	2.3	7
1264	Early detection of cancer. <i>Science</i> , 2022, 375, eaay9040.	6.0	291
1265	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	9.4	63
1266	Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. <i>Gastroenterology</i> , 2022, 163, 386-402.e1.	0.6	204
1267	Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100407.	2.0	10
1268	Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer. <i>Surgical Oncology</i> , 2022, 42, 101753.	0.8	4
1269	Multicancer Early detection Panels (MCEDs) in the Primary Care Setting. <i>American Journal of Medicine</i> , 2022, 135, e145-e149.	0.6	8
1270	Development and validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic patients referred urgently from primary care: a diagnostic accuracy study. <i>BMJ Open</i> , 2022, 12, e053590.	0.8	5
1271	Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100399.	2.0	54
1272	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	2.3	13
1273	Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer. <i>Oral Oncology</i> , 2022, 128, 105805.	0.8	16
1275	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	2.2	15
1276	A targeted simulationâ€œextrapolation method for evaluating biomarkers based on new technologies in precision medicine. <i>Pharmaceutical Statistics</i> , 2021, , .	0.7	0
1277	Ultra-Deep Sequencing of Plasma-Circulating DNA for the Detection of Tumor- Derived Mutations in Patients with Nonmetastatic Colorectal Cancer. <i>Cancer Investigation</i> , 2022, 40, 354-365.	0.6	6
1278	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancerâ€œImpact for Diagnosis and Treatment Monitoring. <i>Cancers</i> , 2022, 14, 168.	1.7	5
1279	Circulating Tumor DNA in Oncology. <i>Processes</i> , 2021, 9, 2198.	1.3	0

#	ARTICLE	IF	CITATIONS
1281	Worldwide review with meta-analysis of women's awareness about breast cancer. <i>Patient Education and Counseling</i> , 2022, 105, 1818-1827.	1.0	15
1282	Role sharing between minimally invasive oesophagectomy and organ preservation approach for surgically resectable advanced oesophageal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 108-113.	0.6	2
1283	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. <i>Molecular Oncology</i> , 2022, 16, 2042-2056.	2.1	8
1284	Development of a horizontal data integration classifier for Non-invasive early diagnosis of breast cancer: the RENOVATE study protocol. <i>BMJ Open</i> , 2021, 11, e054256.	0.8	2
1285	A Cost-Effective and Non-Invasive lncRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones. <i>Non-coding RNA</i> , 2021, 7, 80.	1.3	2
1286	Cancer Type Classification in Liquid Biopsies Based on Sparse Mutational Profiles Enabled through Data Augmentation and Integration. <i>Life</i> , 2022, 12, 1.	1.1	15
1287	Mutation enrichment in human DNA samples via UV-mediated cross-linking. <i>Nucleic Acids Research</i> , 2022, 50, e32-e32.	6.5	7
1288	Exosomes: Key tools for cancer liquid biopsy. <i>Biocell</i> , 2022, 46, 2167-2176.	0.4	3
1290	Designing highly multiplex PCR primer sets with Simulated Annealing Design using Dimer Likelihood Estimation (SADDLE). <i>Nature Communications</i> , 2022, 13, 1881.	5.8	9
1291	PltDB: a blood platelets-based gene expression database for disease investigation. <i>Bioinformatics</i> , 2022, 38, 3143-3145.	1.8	0
1292	The future of early cancer detection. <i>Nature Medicine</i> , 2022, 28, 666-677.	15.2	92
1293	Current and Developing Liquid Biopsy Techniques for Breast Cancer. <i>Cancers</i> , 2022, 14, 2052.	1.7	19
1294	Structurally constrained MUC1in Mimetic Antigen as Template for Molecularly Imprinted Polymers (MIPs): A Promising Tool for Cancer Diagnostics. <i>ChemPlusChem</i> , 2022, , e202200068.	1.3	2
1295	Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4284.	1.8	10
1296	Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. <i>EBioMedicine</i> , 2022, 79, 104001.	2.7	54
1309	Liquid biopsy: early and accurate diagnosis of brain tumor. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2347-2373.	1.2	7
1310	Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies. <i>Npj Precision Oncology</i> , 2022, 6, 28.	2.3	17
1311	Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer. <i>Science Advances</i> , 2022, 8, eabm3453.	4.7	39

#	ARTICLE	IF	CITATIONS
1312	Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 512-514.	1.1	11
1314	A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	3
1315	Clinical validation of a next-generation sequencing-based multi-cancer early detection "liquid biopsy" blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study. <i>PLoS ONE</i> , 2022, 17, e0266623.	1.1	20
1318	Molecular genetic testing in colon cancer: clinical aspects. <i>Almanah Kliničeskoj Mediciny</i> , 2022, 50, 1-12.	0.2	1
1319	Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1298-1304.	1.1	14
1320	The History and Future of Basic and Translational Cell-Free DNA Research at a Glance. <i>Diagnostics</i> , 2022, 12, 1192.	1.3	5
1321	Circulating cell-free DNA for cancer early detection. <i>Innovation(China)</i> , 2022, 3, 100259.	5.2	35
1322	Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5343.	1.8	3
1323	Micro/nanofiber fabrication technologies for wearable sensors: a review. <i>Journal of Micromechanics and Microengineering</i> , 2022, 32, 064002.	1.5	5
1324	Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. <i>Proteomes</i> , 2022, 10, 16.	1.7	66
1325	The translational challenges of precision oncology. <i>Cancer Cell</i> , 2022, 40, 458-478.	7.7	38
1326	Circulating Tumor DNA in Pediatric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	1
1327	Current and future colorectal cancer screening strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 521-531.	8.2	102
1328	DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. <i>Clinical Epigenetics</i> , 2022, 14, 61.	1.8	12
1329	Diagnostic potential of nanoparticle aided assays for <scp>MUC16</scp> and <scp>MUC1</scp> glycovariants in ovarian cancer. <i>International Journal of Cancer</i> , 2022, 151, 1175-1184.	2.3	6
1330	Potential clinical utility of liquid biopsies in ovarian cancer. <i>Molecular Cancer</i> , 2022, 21, 114.	7.9	51
1331	Exosomes from prostate cancer cell lines: Isolation optimisation and characterisation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113093.	2.5	11
1332	Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. <i>PLoS ONE</i> , 2022, 17, e0267362.	1.1	6

#	ARTICLE	IF	CITATIONS
1333	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 711-728.	1.8	12
1334	Extracellular Vesicle-Based Multianalyte Liquid Biopsy as a Diagnostic for Cancer. Annual Review of Biomedical Data Science, 2022, 5, 269-292.	2.8	6
1335	CRISPR-Cas-mediated diagnostics. Trends in Biotechnology, 2022, 40, 1326-1345.	4.9	26
1336	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. Critical Reviews in Oncology/Hematology, 2022, 175, 103725.	2.0	1
1337	Single extracellular vesicle analysis for early cancer detection. Trends in Molecular Medicine, 2022, 28, 681-692.	3.5	29
1338	Advances in breast cancer screening modalities and status of global screening programs. Chronic Diseases and Translational Medicine, 2022, 8, 112-123.	0.9	5
1339	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes?. Laboratoriums Medizin, 2022, 46, 255-264.	0.1	6
1340	An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. IScience, 2022, 25, 104437.	1.9	2
1341	Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9. ACS Applied Materials & Interfaces, 2022, 14, 24113-24121.	4.0	5
1342	Biomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area. Journal of Proteome Research, 2022, 21, 1718-1735.	1.8	21
1344	The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies. Diagnostics, 2022, 12, 1363.	1.3	9
1345	Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business?. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1146-1150.	1.1	6
1348	Rationally designed far-red emitting styryl chromones and a magnetic nanoconjugate for strip-based on-site detection of metabolic markers. Journal of Materials Chemistry B, 0, , .	2.9	8
1349	Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy. Current Issues in Molecular Biology, 2022, 44, 2695-2709.	1.0	11
1350	The rising tide of cell-free DNA profiling: from snapshot to temporal genome analysis. Laboratoriums Medizin, 2022, 46, 207-224.	0.1	7
1351	Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. Cancers, 2022, 14, 2885.	1.7	22
1352	Biomaterials-Mediated Tumor Infarction Therapy. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	2
1353	Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends. Archives of Pathology and Laboratory Medicine, 2023, 147, 425-433.	1.2	1

#	ARTICLE	IF	CITATIONS
1354	Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	6
1355	Teaching PCR for Simultaneous Sensing of Gene Transcription and Downstream Metabolites by Cucurbit[8]uril-Mediated Intervention of Polymerase Activity. <i>Analytical Chemistry</i> , 2022, 94, 8715-8723.	3.2	2
1356	On the Cross-Validation Bias due to Unsupervised Preprocessing. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2022, 84, 1474-1502.	1.1	7
1357	Integrating chromatin accessibility states in the design of targeted sequencing panels for liquid biopsy. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1358	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
1359	Early diagnostics and screening for ovarian cancer. <i>Kazan Medical Journal</i> , 2022, 103, 476-483.	0.1	1
1360	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	50
1361	Single-Cell RNA Sequencing of Cerebrospinal Fluid as an Advanced Form of Liquid Biopsy for Neurological Disorders. <i>Brain Sciences</i> , 2022, 12, 812.	1.1	6
1362	The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs. <i>Cancers</i> , 2022, 14, 2951.	1.7	8
1363	Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 670-681.	8.2	106
1364	DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 2918.	1.7	6
1365	Future of Colorectal Cancer Screening: From One-Size-FITs-All to Tailor-Made. , 0, 1, .		4
1366	Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 551-561.	12.5	25
1367	Plasma CXCL14 as a Candidate Biomarker for the Diagnosis of Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1368	Metabolic detection of malignant brain gliomas through plasma lipidomic analysis and support vector machine-based machine learning. <i>EBioMedicine</i> , 2022, 81, 104097.	2.7	12
1369	A novel biorecognition receptor Citropin-A modified impedimetric biosensor for detection of LNCaP prostate cancer cells. <i>Analytical Biochemistry</i> , 2022, 652, 114772.	1.1	1
1371	Circulating cancer biomarkers: current status and future prospects. , 2022, , 409-443.		0
1372	Cancer immunoeediting hypothesis: history, clinical implications and controversies. <i>Central-European Journal of Immunology</i> , 2022, 47, 168-174.	0.4	8

#	ARTICLE	IF	CITATIONS
1373	Methods for the Detection of Circulating Biomarkers in Cancer Patients. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 525-552.	0.8	3
1374	Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications. <i>Cancers</i> , 2022, 14, 3143.	1.7	4
1376	Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. <i>Cancers</i> , 2022, 14, 3275.	1.7	10
1377	Applications of artificial intelligence multiomics in precision oncology. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 503-510.	1.2	9
1378	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
1379	Liquid profiling for cancer patient stratification in precision medicine—current status and challenges for successful implementation in standard care. <i>Laboratoriums Medizin</i> , 2022, 46, 225-236.	0.1	1
1380	Comparison of the somatic mutations between circulating tumor DNA and tissue DNA in Chinese patients with non-small cell lung cancer. <i>International Journal of Biological Markers</i> , 0, , 039361552210990.	0.7	1
1381	Isolation of circulating tumor cells. <i>IScience</i> , 2022, 25, 104696.	1.9	20
1382	Pan-cancer screening by circulating tumor DNA (ctDNA)—recent breakthroughs and chronic pitfalls. <i>Laboratoriums Medizin</i> , 2022, 46, 247-253.	0.1	6
1383	Biofluids Metabolic Profiling Based on PS@Fe ₃ O ₄ —NH ₂ Magnetic Beads-Assisted LDI-MS for Liver Cancer Screening. <i>Analytical Chemistry</i> , 2022, 94, 10367-10374.	3.2	11
1384	Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine. <i>Current Epidemiology Reports</i> , 2022, 9, 200-211.	1.1	2
1385	Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?. <i>Cancers</i> , 2022, 14, 3453.	1.7	4
1386	Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7843.	1.8	15
1387	Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. <i>Cancers</i> , 2022, 14, 3341.	1.7	18
1388	New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary. <i>Cancers</i> , 2022, 14, 3429.	1.7	5
1389	Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. <i>Matrix Biology</i> , 2022, 111, 207-225.	1.5	9
1390	Cell free DNA; diagnostic and prognostic approaches to oncology. <i>Advances in Cancer Biology Metastasis</i> , 2022, 5, 100052.	1.1	4
1391	Personalized Cancer Care. , 2023, , 83-90.		0

#	ARTICLE	IF	CITATIONS
1392	Cancer Epidemiology, Prevention, and Survivorship. , 2023, , 3-14.		1
1393	Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases. Diseases of the Colon and Rectum, 0, Publish Ahead of Print, .	0.7	1
1394	Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Frontiers in Oncology, 0, 12, .	1.3	27
1395	Molecular Biomarkers in Cancer. Biomolecules, 2022, 12, 1021.	1.8	85
1396	An Integrated Patient Triage and Capacity Recommender System for Robust Outpatient Department Service Delivery. , 2022, , .		0
1397	A distinct lipid metabolism signature of acute myeloid leukemia with prognostic value. Frontiers in Oncology, 0, 12, .	1.3	8
1398	Programmable Analysis of MicroRNAs by <i>Thermus thermophilus</i> Argonaute-Assisted Exponential Isothermal Amplification for Multiplex Detection (TEAM). Analytical Chemistry, 2022, 94, 11290-11297.	3.2	19
1399	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics, 2022, 12, 1799.	1.3	7
1400	Profiling disease and tissue-specific epigenetic signatures in cell-free DNA. Laboratoriums Medizin, 2022, 46, 283-294.	0.1	5
1402	A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis. British Journal of Cancer, 2022, 127, 1550-1556.	2.9	13
1403	MiRNA-based "fitness score" to assess the individual response to diet, metabolism, and exercise. Journal of the International Society of Sports Nutrition, 2022, 19, 455-473.	1.7	4
1404	Circulating tumour DNA " looking beyond the blood. Nature Reviews Clinical Oncology, 2022, 19, 600-612.	12.5	97
1405	Blood protein biomarkers in lung cancer. Cancer Letters, 2022, 551, 215886.	3.2	15
1406	Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers. Cancers, 2022, 14, 3854.	1.7	0
1407	Current Screening Strategies for Pancreatic Cancer. Biomedicines, 2022, 10, 2056.	1.4	5
1408	Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 9006.	1.8	9
1409	Circulating Tumor DNA Allele Fraction. American Journal of Pathology, 2022, 192, 1368-1378.	1.9	8
1410	Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research. Anticancer Research, 2022, 42, 4207-4216.	0.5	2

#	ARTICLE	IF	CITATIONS
1411	Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA. <i>Nature Communications</i> , 2022, 13, .	5.8	13
1412	Editorial: Liquid biopsy: A tool for better understanding of the metastatic process ecosystem. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1413	The evolving role of liquid biopsy in lung cancer. <i>Lung Cancer</i> , 2022, 172, 53-64.	0.9	19
1414	Development of electroactive materials-based immunosensor towards early-stage cancer detection. <i>Coordination Chemistry Reviews</i> , 2022, 471, 214723.	9.5	25
1415	Exosome-driven liquid biopsy for breast cancer: Recent advances in isolation, biomarker identification and detection. , 2022, 1, 100006.		9
1416	Detection and localization of early- and late-stage cancers using platelet RNA. <i>Cancer Cell</i> , 2022, 40, 999-1009.e6.	7.7	34
1417	A combined iterative sure independence screening and Cox proportional hazard model for extracting and analyzing prognostic biomarkers of adenocarcinoma lung cancer. <i>Healthcare Analytics</i> , 2022, 2, 100108.	2.6	0
1418	Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 179, 103800.	2.0	4
1419	Seroprotein Profiling of Lung, Pancreatic, And Colorectal Cancers Reveals Alcohol Consumption-Mediated Perturbations in Early-Stage Cancer Detection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1420	Identification and Validation of Prognosis Markers for Adenocarcinoma Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1421	A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. <i>Cancers</i> , 2022, 14, 4128.	1.7	8
1422	Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1578-1590.	1.3	2
1423	Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9952.	1.8	29
1424	Liquid biopsy: current technology and clinical applications. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	158
1425	DEEP Surveillance of Brain Cancer Using Self-Functionalized 3D Nanoprobes for Noninvasive Liquid Biopsy. <i>ACS Nano</i> , 2022, 16, 17948-17964.	7.3	8
1426	Self-assembled micelles of the natural medicine ginsenosides for cancer metastasis therapy. <i>Journal of Industrial and Engineering Chemistry</i> , 2022, 116, 303-309.	2.9	6
1427	New Perspectives on the Importance of Cell-Free DNA Biology. <i>Diagnostics</i> , 2022, 12, 2147.	1.3	24
1428	Immunoarray Measurements of Parathyroid Hormone-Related Peptides Combined with Other Biomarkers to Diagnose Aggressive Prostate Cancer. <i>Analytical Chemistry</i> , 2022, 94, 12788-12797.	3.2	3

#	ARTICLE	IF	CITATIONS
1429	Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer. <i>Cells</i> , 2022, 11, 2871.	1.8	6
1430	Blood-based DNA methylation profiling for the detection of ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 167, 295-305.	0.6	4
1431	Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring. <i>Healthcare (Switzerland)</i> , 2022, 10, 1714.	1.0	11
1432	Noncoding RNome as Enabling Biomarkers for Precision Health. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10390.	1.8	5
1433	Considerations in the implementation of multicancer early detection tests. <i>Future Oncology</i> , 0, , .	1.1	2
1434	Development of a Classifier for the Diagnosis of Oncological Diseases Based on Blood Protein Markers. , 2022, , .		0
1435	Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	28
1436	Dietary Intervention for Preventing Colorectal Cancer: A Practical Guide for Physicians. <i>Journal of Cancer Prevention</i> , 2022, 27, 139-146.	0.8	6
1437	The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Journal of Liver Cancer</i> , 2022, 22, 167-177.	0.3	1
1438	Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer. <i>Biomedical Journal</i> , 2023, 46, 100563.	1.4	5
1439	Hydroxymethylation profile of cell-free DNA is a biomarker for early colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1440	Sessile droplet array for sensitive profiling of multiple extracellular vesicle immuno-subtypes. <i>Biosensors and Bioelectronics</i> , 2022, 218, 114760.	5.3	0
1441	Mammography Screening. <i>Medical Radiology</i> , 2022, , 43-68.	0.0	2
1442	Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	3
1444	SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. <i>Journal of Thoracic Oncology</i> , 2023, 18, 31-46.	0.5	28
1445	Genomic Profiling and Liquid Biopsies for Breast Cancer. <i>Surgical Clinics of North America</i> , 2022, , .	0.5	0
1446	Cell-free DNA 5-hydroxymethylcytosine as a marker for common cancer detection. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	2
1449	Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 929-942.	0.9	0

#	ARTICLE	IF	CITATIONS
1450	Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. <i>Cancer Medicine</i> , 0, , .	1.3	2
1451	Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives. <i>European Journal of Cancer</i> , 2023, 178, 91-113.	1.3	18
1452	Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 1830.	3.4	39
1453	Advances in Cell-Free DNA. <i>Advances in Molecular Pathology</i> , 2022, 5, 141-148.	0.2	1
1454	Precision gynecologic oncology: circulating cell free DNA epigenomic analysis, artificial intelligence and the accurate detection of ovarian cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1455	A Fast Accurate Deep Learning Framework for Prediction of All Cancer Types. <i>IEEE Access</i> , 2022, 10, 122586-122600.	2.6	2
1456	Algorithms for And Challenges in the Analysis of Markers in Personalized Health Care. , 2022, , 203-229.		0
1457	The future of brain tumor liquid biopsies in the clinic. <i>Neuro-Oncology Advances</i> , 2022, 4, ii4-ii5.	0.4	0
1459	Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives. <i>Cells</i> , 2022, 11, 3493.	1.8	5
1460	Molecular Management of High-Grade Serous Ovarian Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13777.	1.8	6
1461	A novel blood based triage test for colorectal cancer in primary care: a pilot study. <i>BJGP Open</i> , 2023, 7, BJGPO.2022.0077.	0.9	1
1462	Cell-free Nucleic Acids in Cancer. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 669-686.	0.7	0
1463	Clinical usefulness of circulating tumor markers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 895-905.	1.4	6
1465	Evaluation of cell-free DNA approaches for multi-cancer early detection. <i>Cancer Cell</i> , 2022, 40, 1537-1549.e12.	7.7	76
1466	Counting unique molecular identifiers in sequencing using a multi-type branching process with immigration. <i>Journal of Theoretical Biology</i> , 2023, 558, 111365.	0.8	2
1467	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2022, , 895-915.		0
1468	Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays. <i>Molecular and Cellular Probes</i> , 2023, 67, 101888.	0.9	3
1469	Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men. <i>Cancers</i> , 2022, 14, 5797.	1.7	6

#	ARTICLE	IF	CITATIONS
1470	Model-based screening for pancreatic cancer in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 0, 1-8.	0.6	1
1471	Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	16
1472	Programmable Microparticle Array for In Situ Modification and Multiple miRNA Detection. <i>ACS Sensors</i> , 2022, 7, 3654-3659.	4.0	9
1473	Prediction of tissue-of-origin of early stage cancers using serum miRNomes. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	1.4	10
1474	Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques. <i>Cancers</i> , 2022, 14, 6025.	1.7	11
1475	The Role of Cell-Free DNA in Cancer Treatment Decision Making. <i>Cancers</i> , 2022, 14, 6115.	1.7	10
1476	Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	2
1477	The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients. <i>Diagnostics</i> , 2022, 12, 3042.	1.3	14
1478	PAM-independent ultra-specific activation of CRISPR-Cas12a via sticky-end dsDNA. <i>Nucleic Acids Research</i> , 2022, 50, 12674-12688.	6.5	11
1479	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 146.	1.8	3
1481	Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1482	Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, .	2.3	13
1483	Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1484	Noninvasive detection of any-stage cancer using free glycosaminoglycans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	23
1485	Oral mycobiota and pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
1486	Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer. <i>Cancers</i> , 2022, 14, 6094.	1.7	4
1487	CRAG: de novo characterization of cell-free DNA fragmentation hotspots in plasma whole-genome sequencing. <i>Genome Medicine</i> , 2022, 14, .	3.6	6
1488	Lossless enrichment of trace analytes in levitating droplets for multiphase and multiplex detection. <i>Nature Communications</i> , 2022, 13, .	5.8	29

#	ARTICLE	IF	CITATIONS
1490	Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	9
1492	Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. <i>Journal of the National Cancer Institute</i> , 2023, 115, 250-257.	3.0	11
1493	Serum protein profiling of lung, pancreatic, and colorectal cancers reveals alcohol consumption-mediated disruptions in early-stage cancer detection. <i>Heliyon</i> , 2022, 8, e12359.	1.4	2
1494	A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. <i>Nature Communications</i> , 2022, 13, .	5.8	27
1495	How to detect cancer early using cell-free DNA. <i>Cancer Cell</i> , 2022, 40, 1464-1466.	7.7	4
1496	Emerging Tests for Noninvasive Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 604-616.	2.4	9
1497	Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis. <i>Nature Communications</i> , 2022, 13, .	5.8	13
1498	Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 923.	1.8	0
1499	Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. <i>Seminars in Cancer Biology</i> , 2023, 88, 187-200.	4.3	36
1500	Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. <i>Diagnostics</i> , 2023, 13, 215.	1.3	3
1501	The non-invasive diagnosis of colorectal cancer via a SOX9-based gene panel. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
1502	Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1504	Circulating DNA fragmentomics and cancer screening. <i>Cell Genomics</i> , 2023, 3, 100242.	3.0	15
1505	<scp>MiR</scp>â€¹38â€¹5p suppresses the progression of lung cancer by targeting <scp>SNIP1</scp>. <i>Thoracic Cancer</i> , 2023, 14, 612-623.	0.8	7
1506	Research trend of circulating tumor DNA associated with breast cancer from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1507	Role of epigenetics in pancreatic ductal adenocarcinoma. <i>Epigenomics</i> , 2023, 15, 89-110.	1.0	4
1509	Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era. <i>Medical Sciences (Basel, Switzerland)</i> , 2023, 11, 8.	1.3	2
1510	Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	15

#	ARTICLE	IF	CITATIONS
1511	A synthesis of evidence for cancer-specific screening interventions: A Preventive Medicine Golden Jubilee Review. <i>Preventive Medicine</i> , 2023, 167, 107395.	1.6	3
1512	Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103899.	2.0	2
1513	lncRNAs: A Novel Class of Small Non-coding RNAs With Real Translational Potential. <i>Journal of Surgical Research</i> , 2023, 284, 237-244.	0.8	3
1514	Cancer Serum Atlas-Supported Precise Pan-Targeted Proteomics Enable Multicancer Detection. <i>Analytical Chemistry</i> , 0, , .	3.2	1
1515	Chromatin-Accessible miRNA Regulons Driving Thyroid Tumorigenesis and Progression. <i>Journal of the American College of Surgeons</i> , 2023, 236, 732-750.	0.2	2
1516	Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions. <i>Clinical Lung Cancer</i> , 2023, 24, 209-217.	1.1	4
1517	Controlling Gastric Cancer in a World of Heterogeneous Risk. <i>Gastroenterology</i> , 2023, 164, 736-751.	0.6	17
1518	Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2505.	1.8	21
1519	Introduction on Cancer Immunodiagnosis. , 2023, , 1-24.		0
1520	Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. <i>Communications Medicine</i> , 2023, 3, .	1.9	2
1521	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
1522	Molecular Computation for Molecular Classification. <i>Advanced Biology</i> , 2023, 7, .	1.4	7
1523	AI as a Novel Approach for Exploring ccFNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology. , 2023, , 73-91.		1
1524	Early Diagnosis of Pancreatic Cancer: Clinical Premonitions, Timely Precursor Detection and Increased Curative-Intent Surgery. <i>Cancer Control</i> , 2023, 30, 107327482311547.	0.7	7
1525	Circulating Tumour DNA: A Promising Cancer Biomarker. , 2023, , 100-114.		0
1526	MMP-9 as Prognostic Marker for Brain Tumours: A Comparative Study on Serum-Derived Small Extracellular Vesicles. <i>Cancers</i> , 2023, 15, 712.	1.7	6
1527	Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA. <i>Cancers</i> , 2023, 15, 817.	1.7	4
1528	Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach. <i>Cancers</i> , 2023, 15, 761.	1.7	10

#	ARTICLE	IF	CITATIONS
1529	A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?. <i>Cancers</i> , 2023, 15, 664.	1.7	12
1531	Blood-Based Cancer Screening/Early Cancer Detection. , 2023, , 1-31.		0
1532	Impact of Whole Genome Doubling on Detection of Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2023, 15, 1136.	1.7	2
1533	Clearance Profile of Circulating Tumor Human Papillomavirus DNA During Radiotherapy Predicts Clinical Outcomes in Human Papillomavirus-Related Oropharyngeal Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
1534	Frontiers in mass spectrometry-based clinical proteomics for cancer diagnosis and treatment. <i>Cancer Science</i> , 2023, 114, 1783-1791.	1.7	6
1535	Multiplexed analysis of EV reveals specific biomarker composition with diagnostic impact. <i>Nature Communications</i> , 2023, 14, .	5.8	22
1536	Modeled residual current cancer risk after clinical investigation of a positive multicancer early detection test result. <i>Cancer</i> , 2023, 129, 2056-2063.	2.0	2
1537	Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. <i>Gastroenterology</i> , 2023, 164, 752-765.	0.6	17
1538	Can New Technology Detect Cancer Sooner?. , 2023, 10, 6-10.		0
1539	Bridging biological cfDNA features and machine learning approaches. <i>Trends in Genetics</i> , 2023, 39, 285-307.	2.9	25
1540	Liquid Biopsy for Early Diagnosis of Hepatocellular Carcinoma: Current State and Future Perspectives. <i>Current Chinese Science</i> , 2023, 3, 420-443.	0.2	0
1541	Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. <i>Pathology Research and Practice</i> , 2023, 245, 154455.	1.0	1
1542	Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 2241-2260.	1.4	4
1543	Pan-targeted quantification of deep and comprehensive cancer serum proteome improves cancer detection. <i>View</i> , 2023, 4, .	2.7	1
1544	Application of Nanomaterials for Food Packaging. , 0, 26, 495-502.		0
1545	Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants. <i>Cancer Investigation</i> , 2023, 41, 232-248.	0.6	6
1546	rBC2LCN-reactive SERPINA3 is a glycobiomarker candidate for pancreatic ductal adenocarcinoma. <i>Glycobiology</i> , 2023, 33, 342-352.	1.3	1
1547	Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer. <i>Lung Cancer</i> , 2023, 178, 28-36.	0.9	11

#	ARTICLE	IF	CITATIONS
1548	Interval Breast Cancers Versus Screen Detected Breast Cancers: A Retrospective Cohort Study. <i>Academic Radiology</i> , 2023, 30, S154-S160.	1.3	4
1549	Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. <i>Lung Cancer: Targets and Therapy</i> , 0, Volume 14, 11-25.	1.3	4
1550	Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection. <i>Nature Communications</i> , 2023, 14, .	5.8	6
1551	A Novel Approach to Decision-Making on Diagnosing Oncological Diseases Using Machine Learning Classifiers Based on Datasets Combining Known and/or New Generated Features of a Different Nature. <i>Mathematics</i> , 2023, 11, 792.	1.1	4
1552	Expression of Epithelial and Mesenchymal Markers in Plasmatic Extracellular Vesicles as a Diagnostic Tool for Neoplastic Processes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3578.	1.8	3
1553	Liquid biopsies: the future of cancer early detection. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	45
1554	Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma. <i>Future Oncology</i> , 2022, 18, 4399-4413.	1.1	8
1555	Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	10
1557	Increasing the Capture Rate of Circulating Tumor DNA in Unaltered Plasma Using Passive Microfluidic Mixer Flow Cells. <i>Langmuir</i> , 2023, 39, 3225-3234.	1.6	1
1558	Multiplex Identification of Post-Translational Modifications at Point-of-Care by Deep Learning-Assisted Hydrogel Sensors. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	0
1559	Multiplex Identification of Post-Translational Modifications at Point-of-Care by Deep Learning-Assisted Hydrogel Sensors. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	3
1560	Liquid Biopsies in Lung Cancer. <i>Cancers</i> , 2023, 15, 1430.	1.7	7
1561	Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. <i>Annals of Oncology</i> , 2023, 34, 486-495.	0.6	11
1562	Cancer Diagnostics. , 2023, , 459-481.		0
1563	Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsamples for Earlier Pancreatic Cancer Detection. <i>ACS Sensors</i> , 2023, 8, 1085-1100.	4.0	4
1564	Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes. <i>Metabolites</i> , 2023, 13, 362.	1.3	0
1565	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 102-138.	0.5	14
1566	Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2023, 23, 339-349.	1.1	1

#	ARTICLE	IF	CITATIONS
1567	Breast Cancer Risk Assessment Models and Multi-Cancer Early Detection Tests. , 2023, , 29-43.		0
1568	Biomarkers in lung cancer screening: a narrative review. <i>Current Challenges in Thoracic Surgery</i> , 0, 5, 5-5.	0.2	7
1569	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1276-1285.	0.6	0
1570	Liquid Biopsies, Novel Approaches and Future Directions. <i>Cancers</i> , 2023, 15, 1579.	1.7	18
1572	Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5160.	1.8	3
1573	A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach. <i>Pharmaceutics</i> , 2023, 15, 868.	2.0	21
1574	Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	7
1576	From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. <i>Cell</i> , 2023, 186, 1772-1791.	13.5	54
1577	Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia. , 2023, , 157-220.		0
1578	Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	11
1580	Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers. <i>Cancer Research and Treatment</i> , 2023, 55, 367-384.	1.3	1
1581	Telomere Length Changes in Cancer: Insights on Carcinogenesis and Potential for Non-Invasive Diagnostic Strategies. <i>Genes</i> , 2023, 14, 715.	1.0	9
1582	Exact Probability Distribution for the ROC Area under Curve. <i>Cancers</i> , 2023, 15, 1788.	1.7	5
1583	Minimally invasive approaches for the early detection of endometrial cancer. <i>Molecular Cancer</i> , 2023, 22, .	7.9	9
1584	Editorial: Retrieving meaningful patterns from big biomedical data with machine learning approaches. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
1585	Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. <i>Cells</i> , 2023, 12, 935.	1.8	12
1587	Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers. <i>Biosensors</i> , 2023, 13, 398.	2.3	16
1588	Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. <i>Scientific Reports</i> , 2023, 13, .	1.6	3

#	ARTICLE	IF	CITATIONS
1589	Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease—From Early Cancer Detection to Individualized Cancer Treatment. <i>Cancers</i> , 2023, 15, 1924.	1.7	1
1590	Ratiometric electrochemical OR gate assay for NSCLC-derived exosomes. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	6
1591	DNA-framework-based multidimensional molecular classifiers for cancer diagnosis. <i>Nature Nanotechnology</i> , 2023, 18, 677-686.	15.6	27
1592	Analytical device miniaturization for the detection of circulating biomarkers. , 2023, 1, 481-498.		11
1593	Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	11
1594	Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. <i>Biomedicines</i> , 2023, 11, 1069.	1.4	1
1595	Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers. <i>Metabolomics</i> , 2023, 19, .	1.4	1
1596	Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1598	Detection of rare mutations, copy number alterations, and methylation in the same template DNA molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	8
1599	Multicancer Early Detection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, , .	2.4	0
1600	Multi-cancer Early Detection Tests, Primary Care, and Shared Decision Making. <i>Annals of Internal Medicine</i> , 2023, 176, 718-720.	2.0	4
1601	DEcancer: Machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection. <i>IScience</i> , 2023, 26, 106610.	1.9	5
1602	Multiplex Digital Methylation—Specific PCR for Noninvasive Screening of Lung Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	8
1603	Cancer driver mutations: predictions and reality. <i>Trends in Molecular Medicine</i> , 2023, 29, 554-566.	3.5	14
1604	A View on Drug Development for Cancer Prevention. <i>Cancer Discovery</i> , 2023, 13, 1058-1083.	7.7	2
1607	Enrichment of Circulating Tumor Cells of Lung Cancer and Correlation With Serum Leukomonocyte and Tumor Biomarkers: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311678.	0.8	2
1608	Diagnosis of Cancer. , 2023, , 96-121.		0
1609	Improving outcomes in patients with oesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 390-407.	12.5	13

#	ARTICLE	IF	CITATIONS
1610	Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100701.	0.7	0
1611	Potential utility of risk stratification for multicancer screening with liquid biopsy tests. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	1
1618	Precision medicine-based cancer care. , 2024, , 272-283.		0
1629	Proteomics and Protein Biomarkers in Cancer Metastasis. , 2023, , 1-34.		0
1630	Circulating tumour cells for early detection of clinically relevant cancer. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 487-500.	12.5	29
1632	Case Report: Early detection of lung carcinoid in an asymptomatic individual by blood-test initiated PET-CT imaging. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1644	Toward a Dielectric Modeling of Ovarian Tumors Using the Mathematical Models of the Blood-Based Biomarker CA125 and the Blood-Borne Tumor-Shed Biomarker SEAP. <i>Lecture Notes in Mechanical Engineering</i> , 2023, , 449-461.	0.3	0
1653	Liquid biopsy in cancer diagnosis, therapy and prognosis. , 2024, , 484-494.		0
1666	Biomarkers for Early Detection of Pancreatic Cancer: A Review. , 2023, , .		0
1667	Screening of Gastric Cancer. , 2023, , 9-12.		0
1669	Potential Value and Application of Liquid Biopsy in Tumor, Neurodegeneration, and Muscle Degenerative Diseases. <i>Methods in Molecular Biology</i> , 2023, , 317-335.	0.4	0
1689	Redefining precision radiotherapy through liquid biopsy. <i>British Journal of Cancer</i> , 2023, 129, 900-903.	2.9	4
1703	Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine. <i>Chemical Society Reviews</i> , 2023, 52, 5706-5743.	18.7	7
1705	ctDNA and Lung Cancer. <i>Current Cancer Research</i> , 2023, , 511-537.	0.2	0
1709	Opportunities for Liquid Biopsies to Meet the Challenges of Precision Medicine. <i>Current Cancer Research</i> , 2023, , 443-460.	0.2	0
1721	Early Cancer Detection: Challenges and Opportunities. <i>Current Cancer Research</i> , 2023, , 619-631.	0.2	1
1731	Minimal residual disease in solid tumors: an overview. <i>Frontiers of Medicine</i> , 2023, 17, 649-674.	1.5	0
1751	Microfluidic Chips as Point-of-Care Testing for Develop Diagnostic Microdevices. , 2024, , 115-128.		0

#	ARTICLE	IF	CITATIONS
1753	i-Biomarker - Multi Cancer Early Detection as a Data Science with AI Problem. , 0, , .		0
1756	Biomarkers of Exposure, Effect, and Susceptibility. , 2023, , .		0
1765	Local Onco-Sphere: Tumorâ€™Secretome Interaction. , 2023, , 101-124.		0
1789	Comparative Analysis of Machine Learning Models for Early Prediction of Cancer. , 2023, , .		0
1796	Recent Advancements in AI-Assisted Drug Design and Discovery Systems. Advanced Technologies and Societal Change, 2023, , 19-36.	0.8	0
1806	An overview of current development and barriers on liquid biopsy in patients with early-stage non-small-cell Lung cancer. , 2023, 2, .		0
1808	Nanomaterials in Cancer Therapy. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 217-248.	0.1	0
1812	Global impact and application of Precision Healthcare. , 2024, , 209-228.		0
1814	Molecular Techniques/Molecular Diagnostics for Surgical Pathologists: An Overview. , 2023, , 1-68.		0
1841	Circulating Tumor DNA in Lymphoma. Molecular Pathology Library, 2023, , 395-426.	0.1	0
1845	A journey from omics to clinicomics in solid cancers: Success stories and challenges. Advances in Protein Chemistry and Structural Biology, 2024, , 89-139.	1.0	0
1848	Ovarian Cancer Screening in the General Population. , 2023, , 77-94.		0
1849	Gastric Cancer Screening. , 2023, , 617-624.		0
1854	Krebsdiagnostik. , 2024, , 525-551.		0
1859	Artificial intelligence in cancer research and precision medicine. , 2024, , 1-23.		0
1860	Artificial intelligence in the oncology workflow: Applications, limitations, and future perspectives. , 2024, , 91-111.		0
1871	Plasmonic Nanobiosensors for Early Diagnosis of Cancers. , 2024, , 1-49.		0